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In the liver, insulin is responsible for maintaining glucose homeostasis by activating glycogen 
synthesis and inhibiting de novo glucose synthesis. Interruption or improper functioning of the 
insulin signalling pathway is one mechanism by which insulin resistance (inadequate response 
of target tissues to normal insulin levels) occurs. Prolonged exposure to glucocorticoids (GCs) 
has been linked to increased hepatic glucose production, and subsequently insulin resistance. 
Furthermore, chronic inflammation (represented by pro-inflammatory cytokines) has been 
implicated in the interruption of insulin signalling, also leading to insulin resistance. However, 
these two biological mediators, which are seldom present in isolation, serve opposing functions 
in the body with GCs having anti-inflammatory action. The fact that chronic stress and chronic 
inflammation result in the same consequence in the form of insulin resistance led us to question 
whether these biological mediators are able to co-regulate insulin signalling at key insulin 
regulated nodes namely, AKT- and GSK-3 protein expression and phosphorylation as well as 
the G6Pase mRNA expression in both murine (BWTG3) and human (HepG2) hepatoma cell 
lines. Overall, co-regulation by the GCs and cytokines was observed at all nodes except GSK-
3. The results, however, were GC, cytokine, and cell line specific. As expected, antagonistic 
behaviour was displayed between the GCs and cytokines, but interestingly, co-operative effects 
were also observed. Whether these biological mediators lead to an insulin resistant state when 
present simultaneously in vivo, remains to be determined.  
  





In die lewer is insulien verantwoordelik vir die handhawing van glukose-homeostase deur 
glikogeen-sintese te aktiveer en de novo-glukose-sintese te inhibeer. Onderbreking of 
onbehoorlike werking van die insulienseinweg is een meganisme waardeur 
insulienweerstandigheid (onvoldoende reaksie van die teikenweefsel op normale 
insulienvlakke) plaasvind. Langdurige blootstelling aan glukokortikoïede (GC’s) is gekoppel 
aan verhoogde lewerglukoseproduksie, en gevolglik insulienweerstandigheid. Voorts word 
daar gedink dat chroniese inflammasie (verteenwoordig deur pro-inflammatoriese sitokiene) 
die onderbreking van die insuliensein tot gevolg het, wat ook tot insulienweerstandigheid lei. 
Hierdie twee biologiese seintransduksiemolekules, wat selde in isolasie teenwoordig is, dien 
egter teenoorgestelde funksies in die liggaam, met GC’s wat ’n anti-inflammatoriese werking 
het. Die feit dat chroniese spanning en chroniese inflammasie dieselfde gevolg het, in die vorm 
van insulienweerstandigheid, het ons laat twyfel of hierdie biologiese molekules die vermoë 
het om mede-reguleerders te kan wees van insulienseinsending by sleutel-insuliengereguleerde 
nodusse, naamlik AKT- en GSK-3 proteïen-uitdrukking en fosforilering sowel as die G6Pase 
mRNA-uitdrukking in beide muriene (BWTG3) en menslike (HepG2) hepatoom-sellyne. In 
die algemeen is mede-regulering deur die GC’s en sitokiene by alle nodusse waargeneem, 
behalwe GSK-3. Die resultate was egter GC-, sitokien- en sellyn-spesifiek. Soos verwag is 
antagonistiese gedrag tussen die GC’s en sitokiene vertoon, maar interessant genoeg is 
samewerkingseffekte ook waargeneem. Of hierdie biologiese molekules tot ’n 
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1.1 Introduction  
The International Diabetes Federation reported that around 90% of all diabetes cases is type 2 
diabetes mellitus (T2DM), affecting millions of people worldwide, including in South Africa 
(1–4). The physiological features of T2DM include obesity, hypertension, atherosclerosis, and 
dyslipidaemia (5) to name but a few. Insulin resistance, which is described as the inability of 
cells to effectively respond to normal insulin concentrations (6), is one of the proposed 
mechanisms that links all of these features and is a major characteristic and predictor of T2DM 
(7–9). In the case of T2DM, insulin resistance goes hand-in-hand with insufficient insulin 
secretion in response to the demand for higher concentrations of insulin needed (1).  
The insulin signalling pathway plays a crucial role in the development of insulin resistance as 
changes to the expression and/or phosphorylation state of any of the key nodes in the signal 
transduction pathway of insulin could lead to insulin resistance (6, 10–15). A number of factors 
have been documented to lead to the development of insulin resistance and subsequently 
T2DM, including increased exposure to glucocorticoids (GCs), whether endogenous or 
exogenous (9, 16, 17), and chronic inflammation (9, 18–21).   
GCs for example, have been shown to cause a decrease in insulin sensitivity in insulin target 
tissues (22). In the liver, increased concentrations of GCs results in increased hepatic glucose 
production as a consequence of increased gluconeogenesis and glycogen breakdown (15, 21, 
23, 24). Decreased insulin sensitivity in adipose tissue due to over-exposure to GCs, results in 
decreased glucose uptake as well as increased lipolysis (25, 26). The inability of skeletal 
muscle cells to effectively take up glucose, is a consequence of reduced insulin sensitivity by 
GCs (27, 28). Moreover, a decrease in glycogen synthesis as well as an increase in proteolysis 
in skeletal muscle cells occurs (29). All of these lead to the development of hyperglycaemia 
and subsequent development of T2DM (6, 28, 30). 
Similar to GCs, chronic inflammation is associated with the development of insulin resistance 
(8, 31–33). A known mechanism by which inflammation causes insulin resistance in insulin 
target tissues is by interfering with insulin signal transduction (8, 31, 32, 34). Chronic 
expression of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-) and 
interleukin-6 (IL-6) have been linked to the suppression of insulin signalling (8, 20, 34–36). 
These inflammatory mediators have been proposed to target multiple nodes in the insulin 
signalling pathway thereby negatively affecting any downstream insulin signalling and 
resulting in impaired glucose metabolism (37, 38). Inflammatory mediators such as pro-
Stellenbosch University  https://scholar.sun.ac.za
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inflammatory cytokines, through negatively influencing insulin signal transduction have been 
implicated in inducing gluconeogenesis and inhibiting glycogen synthesis (33, 39–41).  
GCs and pro-inflammatory cytokines are well-known for their opposing physiological roles, 
with GCs being used as an anti-inflammatory treatment for decades (42, 43). Thus, it begs the 
question, why/how, despite having antagonistic functions, do the increased exposure to GCs 
and pro-inflammatory cytokines both result in insulin resistance? There is no data available, to 
the best of our knowledge, regarding any co-regulation of insulin signalling by GCs and pro-
inflammatory cytokines. As mentioned earlier, insulin signalling comprises various nodes that 
require careful regulation, which could be targets for GCs and pro-inflammatory cytokines. 
The protein levels of key proteins such as AKT (also known as protein kinase B) can be 
regulated, affecting any downstream signalling (44, 45).  In addition, the activity of this central 
protein is regulated by its phosphorylation status at specific amino acid residues. Full activation 
of AKT for example is achieved when it is phosphorylated at serine 473 and threonine 308, 
which is required for downstream signal amplification and the subsequent metabolic effects of 
insulin  (44, 46, 47). Immediately downstream from AKT is the enzyme glycogen synthase 
kinase-3 (GSK-3), the protein levels and activation status of which can also be regulated and 
possibly targeted (48, 49). Insulin signalling via AKT is responsible for the inactivation of 
GSK-3 through phosphorylation of this downstream protein at specific serine residues thereby 
inactivating its kinase activity and thus preventing the inactivation of glycogen synthase (GS) 
(50). Furthermore, GSK-3 requires phosphorylation at distinct tyrosine residues to be 
considered fully active as a kinase and thereby inactivating GS through phosphorylation and 
consequently inhibiting glycogen synthesis (50, 51). Additionally, in the liver for example, 
insulin signalling leads to the inhibition of gluconeogenesis by preventing the transcription of 
key gluconeogenic enzymes such as glucose-6-phosphatase (G6Pase) through the inhibition of 
transcription factors responsible for their gene regulation (52, 53). This also may be considered 
a node of the pathway which can be regulated and possibly targeted by insulin resistance 
causative agents.  
This review of the literature will focus on how GCs and pro-inflammatory cytokines disrupt 
normal insulin signalling, identifying similar key regulatory targets and convergence in their 
respective signal transduction pathways. But firstly, the insulin signalling pathway will be 
discussed to provide background to unperturbed insulin signalling followed by the molecular 
events involved in establishing insulin resistance.  
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1.2 Function of insulin in insulin target tissues 
Insulin is an anabolic, peptide hormone (6, 54)  and it affects a host of physiological processes, 
such as carbohydrate and lipid metabolism (55). However, it is best known for regulating 
glucose homeostasis (56). The primary driver of insulin secretion is glucose. An increase in 
blood glucose concentration induces glucose-mediated insulin secretion from secretory 
granules in the -cells of the pancreas (6). Insulin has both metabolic and mitogenic effects in 
the body. It is responsible for maintaining normal glucose levels in the blood (metabolic 
effects) as well as cell division and growth (mitogenic effects) (6).  
Insulin has three main target tissues in the body namely the liver, skeletal muscle, and adipose 
tissue. The primary focus of this review will be the effects of insulin in the liver.  
1.2.1 Function of insulin in the liver  
The liver plays a vital role in energy homeostasis, with one of its most essential functions being 
the regulation of glucose input and output, otherwise known as glucose metabolism (57). In 
humans, insulin is secreted into the portal venous system, where 40-80% of this insulin is then 
cleared by the liver. Therefore, the liver is always exposed to higher insulin concentrations than 
other organs (58–60). The main function of insulin in the liver is to inhibit glucose production. 
After a meal, an increase in insulin concentration signals the liver to 1) take up glucose, 2) to 
store this glucose as glycogen, and 3) to halt the de novo synthesis of glucose via 
gluconeogenesis by repressing the mRNA synthesis of key gluconeogenic enzymes such as 
G6Pase and phosphoenolpyruvate carboxykinase (PEPCK) (61, 62).  
1.2.2 Function of insulin in skeletal muscle and adipose tissue 
The main effects of insulin in the muscle and adipose tissue involve carbohydrate, lipid, and 
protein metabolism. These include increasing the rate of glucose transport across the cell 
membrane as well as increasing the rate of glycolysis (29, 63). Insulin’s effect on skeletal 
muscle cells, as in the liver cells, is responsible for an increase in glycogen synthesis (63). In 
response to insulin, adipocytes are responsible for the storage of nutrients in the form of 
triacylglycerol (TAG), a compact and efficient form of carbohydrate storage that is readily 
available to be mobilised in time of need, such as during fasting (47, 63). Insulin also inhibits 
protein synthesis in skeletal muscle and inhibits lipolysis in adipocytes, hereby reducing the 
amount of free fatty acids (FFAs), glycerol and amino acids available to be used as substrates 
for gluconeogenesis (64–67).  
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1.3 Insulin signalling 
The effects of insulin on its target tissues mentioned above involves an intricate and complex 
signalling cascade with many points of regulation, some of which were briefly mentioned in 
the introduction (section 1.1) and depicted in Figure 1.1 (8, 68). The binding of insulin to the 
insulin receptor (IR), an integral membrane protein belonging to the receptor tyrosine kinase 
family, leads to the activation of two key pathways: the phosphoinositide 3-kinase (PI3K)-
AKT pathway, which is the pathway responsible for the metabolic effects of insulin, and the 
Ras-MAPK (mitogen-activated protein kinase) pathway, responsible for the mitogenic effects 
of insulin (68). For the purpose of this thesis, we will focus mainly on the PI3K-AKT pathway. 
Upon reaching insulin-responsive tissues, insulin binds the extracellular, -subunit of the 
dimeric IR. This then consequently leads to the autophosphorylation of the intracellular, -
subunit of the receptor at specific tyrosine residues (69). Adaptor proteins known as insulin 
receptor substrates (IRS) are then recruited to the IR, binding to the plasma membrane via their 
pleckstrin homology (PH) domain, which recognises phosphatidylinositols present in the 
plasma membrane, as well as binding to the phosphorylated tyrosine residues of the IR via their 
phosphotyrosine binding (PTB) domains (30). Binding of the IRS adaptor proteins to the 
ligand-activated IR leads to its own phosphorylation, also at tyrosine residues, thus creating 
binding sites for intracellular proteins containing Src-homology 2 (SH2) domains. IRS 
essentially acts as a protein scaffold linking the membrane-bound ligand-activated receptor to 
intracellular signalling proteins (30, 69). The tyrosine phosphorylated IRS molecules allow for 
the recruitment of PI3K to the membrane and PI3K in turn becomes activated. Activated PI3K 
consequently phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) anchored to the 
cell membrane to generate phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 will activate 
phosphoinositide-dependent kinase 1 (PDK1), which is responsible for the phosphorylation of 
AKT (also referred to as PKB and considered the central protein in the pathway) at its threonine 
308 residue leading to its activation. Additionally, AKT gets phosphorylated at a second site, 
serine 473, by mammalian target of rapamycin (mTOR) complex 2. Both phosphorylation 
events are required for the full activation of AKT, allowing AKT to signal phosphorylation 
control of many downstream metabolic processes, such as gluconeogenesis (44, 46, 47).  




Figure 1.1 Insulin signalling pathway. Insulin binds the insulin receptor (IR) at the extracellular, alpha subunit. This causes 
the autophosphorylation of the receptor at key tyrosine residues on the intracellular, beta subunit. Insulin receptor substrate 
(IRS) proteins are then recruited to the activated IR, acting as a scaffold between the receptor and phosphoinositide 3-kinase 
(PI3K). Recruitment of PI3K to the IRS proteins leads to the activation of the catalytic subunit of PI3K, causing the 
phosphorylation of phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-triphosphate (PIP3). 
PIP3 then recruits AKT to the plasma membrane, allowing for phosphorylation at threonine 308 by phosphoinositide-dependent 
kinase 1 (PDK-1). Furthermore, AKT is phosphorylated at serine 473 by the mammalian target of rapamycin (mTOR) complex 
2. When fully activated, AKT can then phosphorylate transcription factors such as forkhead box protein O1 (FOXO1), 
excluding it from the nucleus and thereby blocking its transcriptional activity and inhibiting the expression of gluconeogenic 
enzymes, such as PEPCK and G6Pase. AKT can also phosphorylate glycogen synthase kinase 3 (GSK-3) at key serine 
residues, which in turn allows glycogen synthase (GS) to be active, which means glycogen can be made. Green P indicates 
activating phosphorylation; Red P indicates inhibitory  
 
The insulin signalling pathway is carefully regulated because it affects a number of critical 
processes in the body, such as metabolism, cell growth, and differentiation (45). Under normal 
physiological conditions, insulin signalling is terminated upon dissociation of insulin that 
results in rapid dephosphorylation of the IR and its substrates (70) as depicted in Figure 1.2A. 
Several protein tyrosine phosphatases (PTPases) can catalyse these dephosphorylation events 
(71, 72). However, scientific studies have mainly focused on the cytoplasmic protein tyrosine 
phosphatase 1B (PTP1B), the negative regulator of the insulin receptor (73–77). Disruption of 
the gene encoding this enzyme in mice has been shown to improve insulin sensitivity and 
increases insulin-dependent tyrosine phosphorylation of the IR and IRS proteins in muscle 
(70). Insulin action can also be temporally controlled by lipid phosphatases that 
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dephosphorylate PIP3 (70). An example of such a phosphatase is SHIP2, a phosphoinositide 
phosphatase, which removes the 5-position phosphate from PIP3, thereby blocking insulin 
action through PIP3 (and not PIP2) which is responsible for the recruitment of subsequent 
signalling proteins including AKT (Fig 1.2). Deletion of the SHIP2 protein in mice results in a 
hypersensitivity to insulin (70). Overproduction of phosphatase and tensin homolog (PTEN) 
also attenuates insulin signalling by dephosphorylating PIP3 in vitro (78) as well as down-
regulating PI3K activity (Fig 1.2) (78–82). Protein phosphatase 2A (PP2A) and PH domain 
leucine-rich repeat protein phosphatase (PHLPP), are phosphatases responsible for the 
dephosphorylation of AKT at serine 473 and/or threonine 308 (69, 83) with PHLPP specifically 
able to dephosphorylate AKT at serine 473 (Fig 1.2) (84, 85). Another mechanism of insulin 
signalling inhibition is through the serine phosphorylation of the IR as well as IRS proteins 
(Fig 1.2) (30, 45). An increase in the inhibitory serine phosphorylation of IR and IRS in 
conjunction with decreased tyrosine kinase activity has been associated with insulin resistance 
(14, 30, 86). This serine phosphorylation inhibits the interaction of the IR and IRS proteins, 
thereby inhibiting further downstream action of the insulin signalling pathway (13, 86, 87). 
  




Figure 1.2 Sites of insulin signalling termination. Multiple sites of regulation exist for insulin signalling. A) protein tyrosine 
phosphatase 1 B (PTP1B) can dephosphorylate tyrosine residues on the insulin receptor (IR) and insulin receptor substrate 
(IRS) proteins. B) The lipid phosphatase SHIP2 and phosphatase and tensin homolog (PTEN) catalyse the dephosphorylation 
of phosphatidylinositol (3,4,5)-triphosphate (PIP3) to phosphatidylinositol (4,5)-bisphosphate (PIP2). C) PTEN is also able to 
downregulate phosphoinositide 3 (PI3)-kinase activity. D) Protein phosphatase 2A (PP2A) and PH domain leucine-rich repeat 
protein phosphatase (PHLLP) can dephosphorylate AKT at its threonine 308 and serine 473 residues. E) Inhibitory serine 
phosphorylation of the IR and IRS proteins. 
 
1.3.1 AKT as the central node of insulin signalling 
AKT is a serine/threonine kinase and provides a link between upstream and downstream insulin 
signalling. As illustrated in Figure 1.1, AKT acts as a central hub for cellular signal 
transduction induced by insulin, relaying the signal that originated at the cell surface to various 
intracellular signalling proteins including nuclear proteins. The activation of AKT is initiated 
when PI3K phosphorylates PIP2 to generate PIP3 at the inner plasma membrane. This allows 
the recruitment of AKT which binds to PIP3 via its PH domain, anchoring it to the plasma 
membrane and allowing it to become phosphorylated at its threonine 308 residue found in the 
activation T-loop, by PDK1, as mentioned earlier (section 1.3) (44, 83, 88–92). In addition, 
AKT is further phosphorylated at serine 473, which is situated in its hydrophobic domain, by 
mTOR2 (Figure 1.1) (90, 92–94). As previously mentioned, (section 1.1 and 1.3) 
phosphorylation at both these sites is integral for the full activation of the kinase activity of 
AKT (44, 46, 47). 
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The fully active AKT will translocate from the cell membrane to the cytosol and the nucleus 
(90), where it is able to phosphorylate numerous downstream substrates responsible for the 
regulation of a plethora of other cellular processes (44–46, 88, 95).  
The cellular processes affected by AKT regarding insulin signalling depends on the cell and 
tissue type involved. In adipose and skeletal muscle cells, for example, AKT signals for the 
translocation of the GLUT4 vesicle to the plasma membrane. Once GLUT4 is incorporated in 
the plasma membrane it allows for the uptake of glucose thereby lowering blood glucose 
concentrations (47, 63, 96). Meanwhile, in the liver, the main function of insulin mediated by 
AKT is to decrease blood glucose concentrations by preventing the de novo synthesis of 
glucose. Activated AKT will phosphorylate the transcription factor forkhead box protein O1 
(FOXO1), targeting it to be exported from the nucleus (97–100) as well as for proteasomal 
degradation (101–103). Removal from the nucleus will prevent FOXO1 from regulating the 
gene expression of key gluconeogenic enzymes, such as G6Pase and PEPCK, thus decreasing 
hepatic glucose production by gluconeogenesis (101–103). Other targets of AKT in the liver 
include the phosphorylation of GSK-3 at key serine residues (serine 21 for GSK-3 and serine 
9 for GSK-3), thereby inactivating GSK-3 and preventing the deactivation of GS and 
subsequent inhibition of glycogen synthesis  (50). It therefore encourages the storage of glucose 
in the form of glycogen by increasing glycolysis and glycogenesis (97, 104). AKT is also 
responsible for the upregulation of sterol regulatory element binding protein 1c (SREBP-1c), 
the lipogenic transcriptional regulator which promotes de novo lipogenesis by augmenting 
transcription of several lipogenic enzymes (55, 66).  
1.3.2 Downstream effects of insulin  
Insulin signalling via AKT targets multiple cellular processes including gluconeogenesis and 
glycogen synthesis. These two metabolic processes are especially important in energy 
metabolism and their dysregulation are commonly associated with insulin resistance (67, 97, 
105) and will be discussed next. 
1.3.2.1 Downstream effect of insulin: gluconeogenesis 
Gluconeogenesis is the process whereby non-carbohydrate substrates (such as glycerol and 
lactate) are converted to glucose and/or glycogen (23). This metabolic pathway is driven by 
several enzymes, with the first reaction catalysed by PEPCK and the last reaction in the 
pathway by G6Pase. Hepatic glucose production takes place in the absence of insulin when the 
body experiences starvation. This is mainly due to the fact that expression of gluconeogenic 
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genes is under hormonal control (61, 98, 99, 106–109) and regulated both transcriptionally and 
translationally (110). Transcription factors essential for gluconeogenesis include cAMP 
response element binding protein (CREB), and nuclear factors such as the GR and the forkhead 
box class Os (FoxOs) of which some are inhibited by insulin (CREB and GR being the 
exceptions) (110). In the absence of insulin and presence of glucagon, binding of glucagon to 
its cognate receptor activates a signalling cascade that generates cyclic AMP (cAMP) through 
the activation of adenylyl cyclase. This second messenger in turn stimulates cAMP-dependent 
protein kinase A (PKA), which subsequently phosphorylates CREB. Phosphorylated CREB 
then binds to the CREB response element (CRE) in the promoter region of its target genes, 
including the genes, PCK1 and G6PC, encoding the gluconeogenic enzymes PEPCK and 
G6Pase, respectively, leading to their increased transcription (111). In the presence of insulin, 
de novo synthesis of glucose is inhibited (66), mainly due to the activation of AKT and 
subsequent phosphorylation of FOXO1 (101, 102). FOXO1 of course as previously mentioned 
is another transcription factor required to induce the transcription of PCK1 and G6PC (66, 97). 
Phosphorylation of FOXO1 by AKT results in its nuclear exclusion, where it can no longer 
bind to DNA and induce transcription of the gluconeogenic genes. FOXO1 phosphorylation 
also targets it for proteasomal degradation (101–103). G6Pase is the enzyme responsible for 
the hydrolysis of glucose 6-phosphate (G-6-P) to glucose, the last step of the metabolic 
pathways critical to the production of glucose in the liver via glycogenolysis and 
gluconeogenesis (112, 113). Glucose and not G-6-P can enter the bloodstream (114). PEPCK 
in turn is responsible for the cytoplasmic conversion of oxaloacetate to phosphoenolpyruvate, 
the rate-limiting step in gluconeogenesis (23). Most metabolic enzymes are regulated either 
allosterically or via posttranslational modification. This is not the case for these two key 
gluconeogenic enzymes, PEPCK and G6Pase, which are mainly regulated at the transcriptional 
level (99, 115). The transcriptional regulation of these genes involve complex interactions of a 
variety of transcription factors such as those mentioned earlier in this section as well as other 
proteins (99). Besides insulin and glucagon, G6PC, and PCK1 gene expression is also regulated 
by GCs (23, 98, 111). GCs signals via the GR, and like FOXO1 is a transcription factor, which 
recognises specific DNA sequences known as GREs within the gene promoter of G6PC and 
PCK1 leading to increased gene expression (98). Ligand-activated GR signalling will be 
discussed in more detail later in this chapter (section 1.5).   
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1.3.2.2 Downstream effect of insulin: glycogen synthesis 
Excess glucose not needed for energy is stored as glycogen in the muscle and the liver. The 
breakdown of glycogen increases the amount of glucose available between meals. Glycogen 
therefore acts as a buffer to help maintain blood-glucose levels since glucose is fundamentally 
the only source of energy for the brain (except during prolonged starvation). Glucose from 
glycogen is readily mobilized and is therefore a good source of energy when required 
immediately (116). 
Glycogen levels are controlled by GS and glycogen phosphorylase (117). GS allows for one 
glucose molecule at a time to combine with glycogen. Two isoforms of this enzyme exist, 
namely GS-a (dephosphorylated and the active form) and GS-b (phosphorylated and the 
inactive form). In its active form, the GS enzyme catalyses the rate limiting step of glycogen 
synthesis (transfer of glucose monomers from UDP-glucose to the terminal branch of the 
glycogen chain via the formation of (1→4) glycosidic bonds) (117, 118). As mentioned 
earlier, GSK-3 is the key regulator in glycogen synthesis and while most kinases are activated 
by phosphorylation, GSK-3 kinase activity is inhibited via AKT-induced serine 
phosphorylation (serine 21 in GSK-3 and serine 9 in GSK-3) at the N-terminal of the 
enzyme (50, 119). Therefore, in the presence of insulin an increase in GS activity is observed 
due to the inability of GSK-3 to phosphorylate GS thereby inhibiting its function (117, 120). 
In resting cells, GSK-3 in its active state is highly phosphorylated at key tyrosine residues 
found in the catalytic loop of the enzyme (tyrosine 279 in GSK-3 and tyrosine 216 in GSK-
3) and basally active (51). In this way it plays a role as a negative regulator of the insulin 
signalling pathway (50). Mutation of either of these residues to alanine results in full 
impairment of GSK-3 kinase activity (48, 121). T2DM is strongly linked to decreased insulin-
stimulated GS activity and glycogen synthesis (50, 122–125).  
Glycogen phosphorylase, which also regulates glycogen concentration, is the key enzyme in 
glycogenolysis, responsible for catalysing the rate-limiting step in glycogen breakdown: the 
hydrolysis of glycogen to generate glucose-1-phosphate and a shortened glycogen molecule. 
This enzyme, like GS, also exists in two isoforms, namely: phosphorylase a (active and 
phosphorylated) and phosphorylase b (inactive and dephosphorylated). The important 
regulators of this enzyme are phosphorylase kinase, which catalyses the phosphorylation 
reaction (phosphorylase b → a) and protein phosphatase, which catalyses the 
dephosphorylation reaction (phosphorylase a → b). Insulin regulates this pathway by activating 
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protein phosphatase 1, resulting in the inactive glycogen phosphorylase b and therefore 
decreased glycogen breakdown (117, 120). 
1.4 Insulin resistance 
1.4.1 Defining insulin resistance 
As mentioned earlier, insulin resistance can be briefly described as the inability of insulin target 
tissues to react to ‘normal’ concentrations of insulin (126). It involves the disruption of specific 
events in the insulin signalling pathway (127). Consequently, the insulin target tissues require 
elevated levels of insulin for adequate glucose disposal (55). Development of insulin resistance 
typically results in a compensatory increase in endogenous insulin production by the pancreas 
(10, 128). 
Risk factors and causes of insulin resistance include obesity (129), an inactive lifestyle, poor 
diet, chronic inflammation (18, 130–132) as well as chronic stress (10, 127, 133–135). 
Conditions that present with insulin resistance include central obesity (15, 130), high blood 
pressure (22, 130), high cholesterol as well as T2DM (the predominant consequence of insulin 
resistance), all of which fall under the blanket term “metabolic syndrome” (130, 136–139). The 
ramifications of insulin resistance include, but are not limited to, hyperglycaemia (7, 104, 140, 
141), hyperinsulinemia (60, 138, 142), dyslipidaemia (22, 143), visceral adiposity, and elevated 
inflammatory markers (15, 130–132). Elevated inflammation therefore appears to be both a 
cause and a result of insulin resistance. 
1.4.2 Mechanisms by which insulin resistance can occur 
There are a few proposed molecular mechanisms by which insulin resistance occurs. These 
include either mutations in the IR or other key proteins in the signalling pathway, antagonists 
of insulin or even reduced expression and/or phosphorylation of the key proteins in the insulin 
signalling pathway (45, 138, 144–147). Furthermore, termination of insulin signalling also 
results in insulin resistance. Serine phosphorylation of the IRS molecules are generally 
involved in negative regulation and interfere with its binding to the IR as these proteins then 
cannot be phosphorylated at the specific tyrosine residues (13, 14, 45). This then causes 
reduced docking of PI3K as well as impaired insulin stimulated glucose transport (mainly in 
muscle and adipose tissue) and decreased glycogen synthesis (primarily in the liver and 
muscle) as well as increased hepatic glucose production due to decreased insulin-stimulated 
inhibition of gluconeogenic genes (14, 19, 148–150).  
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Another mechanism of regulation of the insulin signalling pathway is the phosphorylation and 
subsequent activation of protein tyrosine phosphatases (e.g. PTP1B), responsible for the 
dephosphorylation of tyrosine residues of the IR and the IRS or lipid phosphatases (e.g. SHIP2, 
PTEN, etc) responsible for the dephosphorylation of PIP3 to PIP2 leading to the termination of 
insulin action (70, 76, 78, 82, 148, 151–153). These negative regulators have been shown to be 
upregulated in an insulin resistant state (154, 155). 
In the liver, loss of the IR leads to severe insulin resistance, glucose intolerance, and the 
inability of insulin to inhibit glucose production (156). Deletion of IRS-1 in mice results in 
hepatic insulin resistance manifesting as serum hyperinsulinemia (157), while deletion of the 
IRS-2 protein in mice results in severe hepatic insulin resistance (157) as well as increased 
gluconeogenesis (158). Furthermore it has been found that inactivating mutations in the SH2 
domain of the p85 regulatory subunit of PI3K (159) or deletion of both the p85 and p110 
subunits (160) can result in decreased insulin signalling as well as hyperinsulinemia. Although 
this is not physiologically probable, it highlights the fact that dysregulation of the IR, IRS-1 as 
well as PI3K contributes significantly to insulin resistance (161). 
It is thus clear that disruption of insulin signalling can occur at multiple nodes of the pathway. 
These disruptions can occur at a singular node or at multiple nodes simultaneously, affecting 
the amplitude of the inhibitory effect on insulin signalling, leading to an insulin resistant state 
and subsequent T2DM. Inflammation, which is frequently present in the visceral fat of patients 
with cardiovascular disease and T2DM, is often associated with the aetiology and disease 
progression of insulin resistance and T2DM. This is due to inflammatory mediators such as 
pro-inflammatory cytokines negatively affecting multiple points within the insulin signalling 
pathway (20, 31, 32, 34, 162–167). In addition, the stress response mediated by various 
hormones, which include the corticosteroids or GCs is tightly linked to inflammation (168). A 
hypothesis proposed by P. Black (2002) argues that repeated acute or chronic stress may cause 
the inflammatory response present in T2DM (168). Thus stress hormones such as cortisol 
(GCs) together with pro-inflammatory cytokines, could possibly increase the inhibition of 
insulin signalling leading to T2DM development and progression (168, 169). In the sections to 
follow, the molecular signalling of GCs and pro-inflammatory cytokines will be discussed in 
more detail to provide insight into their molecular mechanism of action. 
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1.5 Glucocorticoids (GCs) 
Endogenous GCs (cortisol in humans and corticosterone in rodents) are hormones produced in 
the adrenal cortex under the control of the hypothalamic-pituitary-adrenal (HPA) axis (Figure. 
1.3) (170–172). Under basal or “unstressed” conditions, GCs are released from the adrenal 
gland (Fig 1.3 –C) in a circadian fashion, with peak concentrations experienced during the 
active phase (i.e. in the morning for humans). Upon physiological and emotional stress, activity 
of the HPA axis is further increased (52). Corticotropin-releasing hormone (CRH) is secreted 
from the hypothalamus (Fig 1.3 –A). CRH then binds its cognate receptor in the anterior 
pituitary, inducing the release of adrenocorticotropic hormone (ACTH) as shown in 
Figure 1.3 -B. ACTH in turn stimulates the adrenal gland to synthesize and secrete cortisol into 
circulation (Fig 1.3 –C) (173–176). Once in the bloodstream, GCs are bound to and transported 
by plasma proteins, which keep them biologically inactive ( 80-90 % bound to corticosteroid-
binding globulin (CBG) and  10 % bound to albumin) (172). Due to their small, lipophilic 
nature, free or unbound GCs in circulation can freely diffuse across the cell membrane and 
exert their biological functions. The actual bioavailability of GCs in the cytoplasm is regulated 
by a careful balance between the active, unbound cortisol and inactive, bound cortisol (172, 
177–179). Furthermore, active cortisol can be converted to inactivate cortisone by an enzyme 
known as 11-hydroxysteroid dehydrogenase (11-HSD). Two 11-HSD isozymes exist, type 
1 and 2, with 11-HSD1 responsible for catalysis of cortisone to cortisol and 11-HSD2 
responsible for the reverse reaction) (176, 178).   
Synthetic GCs, such as dexamethasone (dex) and prednisolone are produced by the 
pharmaceutical industry for use as anti-inflammatory agents. They were developed based on 
the structure of cortisol and mimic the effects thereof (180, 181). Synthetic and endogenous 
GCs differ in their potency, specificity as well as in the fact that most synthetic GCs do not 
bind carrier proteins like CBG (172). In terms of potency, synthetic GCs are usually much 
better activators of the GR than cortisol, mainly due to their higher binding affinity for the GR 
(172, 182, 183). Where specificity is concerned, endogenous GCs are known to activate both 
the GR and the mineralocorticoid receptor (MR), whereas synthetic GCs such as dex almost 
exclusively activate the GR (172, 182, 183). Synthetic GCs like dex are also not subject to 
metabolic processing by 11-HSD1/2 as is the case for endogenous GCs and therefore this has 
a major impact on the bioavailability of synthetic GCs (172, 182–184). However, their 
prolonged use is often associated with complications and undesired side effects such as central 
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obesity, hypertension, and increased hepatic glucose production, which are dependent on the 
duration and dose of the treatment (185, 186). 
GC action is mediated by acting as a ligand for the GR, an intracellular receptor and ligand-
dependent transcription factor. The GR belongs to the steroid receptor family, which is part of 
the nuclear receptor super family (187, 188). Upon activation by ligand, the receptor can act as 
a transcription factor and alter the expression of its target genes. The GR can bind to specific 
DNA sequences known as GREs (187). In the absence of ligand, the GR is part of a large 
heterodimeric complex with several other proteins that dissociates upon ligand binding. 
Additionally, ligand binding also leads to the formation of GR homodimers and the subsequent 
translocation into the nucleus where it can regulate the transcription of specific genes (181). 
Transactivation is mainly believed to occur via direct binding of GR homodimers to the GREs 
within the promoter sequences of GC-responsive genes (172, 188). The ligand-activated GR is 
also responsible for the repression of multiple genes (188). Ligand-activated GR monomers 
can also bind to DNA sequences known as negative GREs (nGREs) in the promoter of the 
target gene (172, 179, 189–193). Furthermore, GR monomers can bind to half-sites on the 
DNA and if there is another transcription factor binding site nearby, the two elements can act 
as a composite site, where either positive or negative interaction between the GR and other 
transcription factor can occur (172, 193–198). Lastly, gene expression can be influenced by 
direct protein-protein interactions with other DNA-bound transcription factors such as 
activator protein 1 (AP-1), signal transducer and activator of transcription (STAT), and nuclear 
factor kappa B (NFB), directly altering the ability of these transcription factors to effectively 
bind DNA, recruit co-factors, and activate or repress gene transcription (188, 193, 199–201). 
This so-called tethering of the GR to other transcription factors occurs in the absence of direct 
DNA binding of the GR (202).  
The anti-inflammatory activity of the GR is generally attributed to the repression of pro-
inflammatory genes by tethering to transcription factors such as AP-1 and NFB thereby 
blocking their transcriptional activation of pro-inflammatory genes (described further in 
section 1.6) (193, 199, 203–206). The anti-inflammatory nature of GCs are also coupled to 
augmented anti-inflammatory cytokine expression by direct binding of the GC-bound GR to 
GREs in the promoter region of several anti-inflammatory genes (43).   
 




Figure 1.3 The stress response/ HPA axis. A) Stress stimulates the hypothalamus to release corticotropin-releasing hormone 
(CRH). B) CRH then acts on the anterior pituitary gland to stimulate the synthesis of adrenocorticotropic hormone (ACTH). 
C) ACTH in turn, acts on the adrenal cortex to induce the secretion of glucocorticoids (such as cortisol in humans) from the 
adrenal cortex. Once secreted, they are able to exert a variety of tissue-specific metabolic effects.Green plus indicates increase. 
1.5.1 Glucocorticoids and insulin resistance 
GCs have longed been associated with T2DM and insulin resistance (24, 186, 188). In fact the 
effect this adrenal steroid has on glucose metabolism and blood glucose levels influenced its 
fitting and explanative name  (207). For example, a study done by Yan, et al., concluded that 
chronic stress was associated with insulin resistance and may further contribute to the 
development thereof (208).  
A well-known metabolic effect of GCs is the upregulation of gluconeogenesis consequently 
leading to increased hepatic glucose production (23, 186, 209–212). The ligand-activated GR 
is the transcription factor responsible for the gene regulation of G6PC and PCK1 (52, 98, 109, 
209, 213–215). The G6PC and PCK1 promoter activation induced by GCs leads to an increase 
in the mRNA and protein levels of these enzymes (186, 216, 217). 
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However, GCs are also capable of influencing glucose metabolism via interfering with insulin 
signalling more directly (218, 219). GCs have been proven to decrease protein expression of 
IRS-1 in rat muscle (220, 221) and adipocyte cell lines (222) as well as decrease tyrosine 
phosphorylation of the IR and IRS-1 in muscle cells (220). Similarly, a study by Giorgino, et 
al., proved that GC-treated rat muscles showed a decrease in tyrosine phosphorylation of IR 
due to a decrease in the total IR protein (223). A study by Miao, Zhang, Lu, et al., observed an 
increase in serine phosphorylation of IRS-1 following GC treatment in liver cells (224). The 
increase in transcription of PTP1B in response to GC treatment has also been demonstrated in 
rat muscle (221).  
Furthermore, treatment with GCs have been shown to decrease AKT protein expression (17) 
as well as phosphorylation at both the threonine 308 and serine 473 sites in adipocytes and 
muscle of rats (17) as well as in their mast cells (218).  
Downstream of AKT, GCs have been proven to affect insulin signalling by reducing the 
insulin-induced GSK-3 inhibitory phosphorylation at serine 9 (17). The authors of this study, 
however, did not investigate the phosphorylation status of the tyrosine residues responsible for 
maximal GSK-3 activity. Nonetheless, the presence of increased concentrations of GCs for 
extended periods of time could lead to disrupted insulin signalling, decreased glycogen 
synthesis as well as increased gluconeogenesis.  
As mentioned in section 1.4.1, obesity is both a cause of, as well as a condition that presents 
with, insulin resistance. It is also a potential link between GC- and inflammation-mediated 
insulin resistance (132) as obesity (characterised by chronic low-grade inflammation) is a 
known side effect of chronic overexposure to GCs (28, 133, 225, 226). 
1.6 Inflammation and pro-inflammatory cytokines 
The inflammatory response can be described as the concerted activation of signalling pathways 
that control inflammatory mediator levels in the resident tissue cells and inflammatory cells 
recruited from the blood. Uncontrolled and sustained acute inflammation is a common 
pathogenesis of many chronic diseases including cardiovascular disease and diabetes, among 
others (227). The inflammatory response is an important part of immunity (228). Obesity, a 
key risk factor in the development of T2DM as well as a side effect of long-term GC use, is 
characterised by chronic low-grade inflammation – increased levels of pro-inflammatory 
cytokines such as TNF- and IL-6 in circulation (229–231). These cytokines are able to 
interfere with normal insulin function and subsequently assist in the development of insulin 
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resistance (21, 232). The term ‘cytokine’ is the general name for polypeptides secreted by cells 
in an effort to upregulate the inflammatory response. They promote systemic inflammation 
(233–235). TNF-α and IL-6 are early release cytokines that are mainly associated with acute 
inflammation (233). However, prolonged exposure to these pro-inflammatory cytokines due to 
a persistent acute inflammatory response, observed with obesity, often results in disrupted 
insulin signalling leading to insulin resistance (225, 227, 233). For this reason, the signalling 
pathways of these two pro-inflammatory pathways will be briefly described in the following 
sections.   
1.6.1 Tumour necrosis factor alpha (TNF-α) 
TNF- is a potent pro-inflammatory cytokine involved in the stimulation of inflammation, 
particularly an acute phase immune response (228, 236). It is also the first cytokine to have 
been reported to represent a link between obesity, inflammation, and diabetes (19, 21). TNF- 
exerts its biological effects by binding to two plasma membrane receptors, TNF-receptor 1 
(TNF-R1) and TNF-receptor 2 (TNF-R2) with the majority of the biological effects mediated 
via TNF-R1 (237). TNF-R1-mediated signalling leads to the activation of the transcription 
factor NFB (237). NFB is normally sequestered in the cytoplasm by members of the inhibitor 
of B (IB) protein family. TNF--induced signalling to NFB involves the activation of IB 
kinase (IKK). Once activated, the IKK subunit of IKK phosphorylates the IKK subunit, 
which leads to its ubiquitination and subsequent proteasomal degradation. This allows NFB 
to translocate into the nucleus where it can activate transcription of NFB responsive genes by 
binding to B sites situated within their promoter regions (237). NFB responsive genes that 
are upregulated by binding of NFB to the B site include IL-6 (238, 239), numerous acute 
phase proteins involved in the acute phase response (240–245), as well as PTP1B (76). Genes 
repressed or downregulated by NFB signalling include G6PC, encoding the gluconeogenic 
enzyme G6Pase (112, 246), and HSD11B2, which encodes for 11-HSD2 that is responsible 
for the conversion cortisone to cortisol (247).  
 
1.6.2 Interleukin-6 (IL-6) 
Like TNF-, IL-6 has also been identified as an important mediator contributing to insulin 
resistance (167). Additionally, and similarly to TNF-α, IL-6 is also an important inducer of the 
acute phase response (163, 168, 248). IL-6 is synthesised and secreted during inflammatory 
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conditions upon stimulation by TNF- (163) and its serum levels positively correlate with the 
degree of obesity and the development of T2DM (163, 249).  Two mechanisms of IL-6 
signalling exists: classic signalling and trans-signalling. IL-6 binds the IL-6 receptor (IL-6R), 
which on its own is not signalling competent. The classical signalling pathway is initiated upon 
the association of the IL-6/IL-6R complex with a second receptor, named glycoprotein 130 
(gp130). Gp130 is expressed on all cells of the body whereas IL-6R is only expressed on certain 
cell types including hepatocytes. Therefore, only IL-6R expressing cells can directly respond 
to IL-6, leading to classic signalling. Trans-signalling involves the use of a soluble IL-6 
receptor (sIL-6R), which is then able to bind gp130 and initiate signalling in cells that do not 
express the membrane bound IL-6R. Gp130 dimerization, upon binding of the IL-6/IL-6R 
complex, leads to the activation of the tyrosine kinase, JAK1, which is constitutively bound to 
the cytoplasmic portion of gp130. After autophosphorylation, JAK1 phosphorylates tyrosine 
residues within the cytoplasmic portion of gp130, leading to the activation of several 
intracellular signalling pathways including the MAPK, PI3K, and the STAT 1 and 3 pathways 
(250–252). STAT3, a transcription factor for example, in the liver supresses the PCK1 and 
G6PC genes (58, 253).  
1.6.3 Inflammatory cytokines and insulin resistance 
Pro-inflammatory cytokines acting via their respective receptors initiate a cascade of molecular 
events as described above, which could influence insulin signalling. STAT3 for example, 
which is activated by IL-6, is also able to upregulate suppressor of cytokine signalling (SOCS) 
3, a negative regulator of cytokine signalling (163), which has also been shown to inhibit 
insulin signalling by directly binding to the phosphotyrosine 960 of the IR via its SH2 domain. 
It therefore prevents IRS1 and IRS2 interaction with the IR (31). Furthermore, the expression 
of SOCS-3 also inhibits autophosphorylation of the IR (34, 163–166). Inhibition of tyrosine 
phosphorylation, by pro-inflammatory cytokines such as TNF- (164) as well as IL-1 (32), 
of IR and IRS proteins in the murine adipocyte 3T3-L1 cells have also been reported. In 
addition, pro-inflammatory cytokines such as IL-1  (32) and IL-6 (167) have been shown to 
decrease phosphorylation of AKT at threonine 308 (32) and serine 473 (167). Meanwhile it has 
also been reported that TNF- induces serine phosphorylation of the IR and IRS-1 through 
activation of p38 MAPK and IKK, which in turn impairs its tyrosine phosphorylation by insulin 
and the subsequent activation of PI3K and AKT in rat myotubes (162). The authors reported 
that the increase in IR serine phosphorylation led to a decrease in glucose uptake due to 
decreased GLUT4 translocation, a hallmark of an insulin resistant state  (162). 
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It is not only the phosphorylation status of insulin signalling mediators that are negatively 
influenced by pro-inflammatory cytokines. The protein levels of key nodes within the insulin 
signalling pathway are also affected. For example, the pro-inflammatory cytokine IL-1 was 
shown to decrease IRS-1 protein expression in 3T3-L1 cells (32). Both IL-6 and TNF- 
decreased the mRNA expression and subsequently the protein expression of IRS-1 in 3T3-L1 
cells (254). Downstream, Medina, et al., demonstrated that treatment of 3T3-L1 cells with 
TNF- resulted in decrease AKT levels (255). 
Further downstream effects of insulin are also negatively regulated by pro-inflammatory 
cytokines such as TNF- and IL-6. Senn, et al., reported that primary hepatocytes treated with 
IL-6 led to a 75% reduction in insulin-induced glycogen synthesis (34). The inflammatory 
cytokine, TNF- has also been shown to induce PTP1B protein expression, which negatively 
affects insulin signalling. Furthermore, treatment with TNF- resulted in the increased 
expression of PTP1B in 3T3-L1 adipocytes as well as the H4IIE a hepatoma cell line (76). In 
contrast, the pro-inflammatory cytokine IL-6, has been implicated in the negative regulation of 
G6Pase in a STAT-dependent manner in vitro and in vivo (256–258) thereby inhibiting the 
de novo production of glucose similar to the function of insulin.  
 
To summarise, pro-inflammatory mediators such as TNF-α and IL-6, like GCs, can influence 
insulin signalling at various nodes within the pathway, which could contribute to a reduction 
in the action of insulin potentially increasing the severity of an insulin resistance pathology as 
well as the rate at which is it manifested.  
1.7 Evidence of co-regulation 
As previously mentioned, GCs and pro-inflammatory cytokines are traditionally known for 
their opposing molecular actions. GCs are often prescribed to patients combating inflammation 
as it is well-known for its anti-inflammatory action. However, as detailed in the previous 
sections, prolonged exposure to GCs or pro-inflammatory cytokines results in the pathogenesis 
of insulin resistance and subsequent T2DM.  
To the best of our knowledge, whether concomitant exposure to both these insulin resistant 
causative agents would influence insulin signalling, is unknown. GCs and pro-inflammatory 
cytokines acting in a co-operative manner, however, is not a novel concept. Acute phase protein 
expression appears to be especially favoured to be co-regulated by these signalling molecules. 
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A number of studies have demonstrated that GCs in the presence of pro-inflammatory 
cytokines such as IL-6 or TNF-α upregulate the expression of positive acute phase proteins 
such as C-reactive protein (CRP) and serum amyloid A (SAA) (244, 259, 260). Liu, et al., 
demonstrated that dex in the presence of either TNF- or IL-6 works co-operatively to increase 
the expression of the murine acute phase protein SIP24/24p3 above levels induced by either of 
the three compounds on their own in 3T3-L1 murine adipocytes (261). Furthermore, another 
study  showed that treatment of HepG2 cells with dex and IL-6 simultaneously increased CRP 
accumulation beyond that of  IL-6 or dex only treatments (262). There also exists evidence for 
the enhancement of SAA transcription when co-treated with dex and either IL-1 or IL-6 
compared to either of the compounds alone (259). These results remain important as 
SIP24/24p3, CRP, and SAA are all acute phase proteins, which have been shown to be elevated 
in and even contribute to an insulin resistant state (263, 264). 
Thus, evidence does exist whereby co-regulation by GCs and pro-inflammatory cytokines have 
been reported, although primarily for acute phase proteins, indicative of GCs assisting with the 
initial stages of the inflammatory response. It would be interesting to examine whether co-
regulation of insulin signalling also occurs as both GCs and cytokines have been reported to 
individually negatively influence insulin signal transduction.  
1.8 Aims of this study 
From the literature described above it is clear that GCs and inflammatory mediators such as 
TNF-α and IL-6 negatively affect insulin signalling. However, what is not clear is whether 
these signalling mediators concomitantly disrupt insulin signalling, which could explain the 
insulin resistance pathology observed in chronic stress and inflammatory conditions. For this 
reason, the current study ventured to determine whether the GCs, dex, corticosterone and 
cortisol and the pro-inflammatory cytokines, TNF-α and IL-6, affect various nodes within 
insulin signal transduction. More specifically, the effect of these cell mediators on insulin 
signalling in the liver was investigated using murine- and human hepatoma cell lines, BWTG3 
and HepG2, respectively. These cell lines served as an in vitro cell model system to study 
hepatic insulin signal transduction.  
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Thus, the aims of the current study were as follows:  
1. To determine whether GCs and the pro-inflammatory cytokines, co-regulate the protein 
expression of AKT, the central molecule involved in insulin signalling. 
2. Whether co-treatment of GCs and cytokines affects AKT phosphorylation at two key 
regulatory residues, threonine 308 and serine 473.  
3. To determine if downstream of the insulin signalling pathway, co-treatment with GCs 
and the pro-inflammatory cytokines affect the protein expression as well as tyrosine 
phosphorylation of GSK-3  
4. To determine whether GCs and pro-inflammatory cytokines co-regulate the expression 
of G6Pase, a key gluconeogenic enzyme.  
 
In Chapter 2 of this thesis the material and methods used will be described, whilst the results 
obtained in the study will be presented in Chapter 3. The discussion and conclusion of the 
current study will be reported in Chapter 4, placing the findings of the current study within the 
context of the literature. In addition, Chapter 4 will also include any future studies which could 
possibly follow from the current study.   
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CHAPTER TWO: MATERIALS AND 
METHODS 
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2.1 Test compounds 
The GCs dex, corticosterone (Cort) and hydrocortisone (F) were obtained from Sigma-Aldrich, 
dissolved in absolute ethanol and stored in glass vials at -20C. TNF- and IL-6 were 
purchased from Thermo Fisher Scientific and reconstituted in 100 nM acetic acid. Cytokines 
were subsequently stored at -20C in supplemented Dulbecco’s Modified Eagle’s Medium 
(DMEM) as described below. 
2.2 Mammalian cell culture 
 2.2.1 Cell growth and maintenance 
The mouse hepatoma cell line, BWTG3, was a generous gift from Guy Haegeman at the 
University of Gent, Belgium (265, 266). The human hepatoma cell line, HepG2, was purchased 
from Cellonex. Both cell lines were cultured in DMEM containing 1000 mg/l glucose and 
supplemented with 10% foetal calf serum (FCS) (Sigma-Aldrich) and 1% 
Penicillin/Streptomycin (Sigma-Aldrich). All cells were maintained at 37C in 75 cm2 tissue 
culture flasks at a relative humidity of 90% and 5% CO2. Cells were tested for mycoplasma 
infection quarterly to ensure that only mycoplasma negative cells are used in all experiments. 
No mycoplasma infection was detected during the course of this study. 
 2.2.2 Treatment conditions 
Cells were seeded using the culture medium as described above, into the appropriate vessels 
depending on the type of experiment. For western blot analysis, cells were seeded at a density 
of 2x105 cells per well in 12-well plates (BioSmart Scientific). For total RNA isolation, cells 
were seeded at a density of 5x105 cells per well in 6-well plates (BioSmart Scientific). Seeding 
in 6-well plates yielded a better total RNA yield than what was observed when using 12-well 
plates. After 24 hours, supplemented DMEM was removed and replaced with serum- and 
antibiotic-free DMEM for 24 hours to ensure any activation of the insulin signalling pathway 
was attributed to that of insulin treatment only and not due to that of the traces of insulin and 
growth hormones present within the FCS. Following this, cells were treated with either a GC, 
a cytokine alone or a combination of a GC and a cytokine for 24 hours (Table 2.1). The vehicle 
control was a combination of 0.1% ethanol and 0.1% supplemented DMEM as these were what 
the GCs and cytokines were prepared in, respectively. Insulin stimulation was done 30 minutes 
before the cells were lysed.  





Table 2.1. Table indicating the treatment conditions for experiments done in this study 
 20 ng/ml TNF-α 20 ng/ml IL-6 
10 nM GC 10 nM GC + TNF-α 10 nM GC + IL-6 
100 nM GC 100 nM GC + TNF-α 100 nM GC + IL-6 






2.3 Total RNA extraction 
Cells were maintained and treated as described in sections 2.2.1 and 2.2.2 respectively.  Total 
RNA was extracted using TRIzol Reagent (Invitrogen), following the manufacturer’s 
instructions. Briefly, 400 l of TRIzol was added to each well, making sure the TRIzol covers 
the surface of the entire well. To ensure adequate lysis of the cells, the plates were stored at -
20C overnight. After thawing on ice, the contents of each well were transferred to a clean, 
RNase-free 1.5ml microcentrifuge tube and 80 l of chloroform was added to each of the 
samples. The samples were then vortexed for 1 minute and then centrifuged at 14 000 x g for 
15 minutes at 4C. After centrifugation, 140 l of the clear aqueous phase (containing the 
RNA) was transferred to a clean, 1.5 ml RNase-free microcentrifuge tube and 200 l of ice-
cold isopropanol was added to each microcentrifuge sample. The samples were again vortexed 
for 1 minute and then stored at -20C for a minimum of 3 days in in order to maximise RNA 
precipitation. The samples were then centrifuged at 14 000 x g for 30 minutes at 4C to allow 
the precipitated RNA to form a pellet.  The supernatant was then discarded, and the pellets 
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washed by adding 500 l of 70% (v/v) ethanol in diethyl pyrocarbonate (DEPC)-treated RNA-
grade water to the microcentrifuge tube containing the pellet. The samples were then vortexed 
for 1 minute. This was followed by centrifugation at 14 000 x g for 5 minutes at 4C. This wash 
step was repeated at least twice to ensure adequate removal of contaminants. After washing the 
pellet, the supernatant was discarded, and the pellet centrifuged to reach maximum speed, 
mimicking the action of a picofuge. Any remaining liquid was removed by pipetting and the 
pellet left to air dry for 10 minutes. The pellet was then dissolved in 20 l DEPC-treated RNA-
grade water and placed on a heating block at 55C for 5 minutes. The RNA concentration was 
then measured using a Nanodrop ND-1000 spectrophotometer. The integrity of the RNA was 
assessed on a 1% (w/v) agarose gel stained with Nancy-520 (267) (Sigma-Aldrich) to confirm 
the presence of undamaged 28S and 18S ribosomal bands. RNA samples were then stored at -
20C for later use. 
2.4 Complementary DNA (cDNA) synthesis from mRNA 
Complementary DNA was synthesized using the ImProm-II reverse transcription kit 
(Promega) as per the manufacturer’s instructions. Briefly, 2 g of total RNA was added to 50 
μg/ml oligo(dT) primers. Nuclease-free water was added to make up the reaction mixture to 
5 l in a thin walled, RNase/DNase-free microcentrifuge tubes for cDNA synthesis (Quality 
Scientific Plastics). This mixture was then heated at 70C for 5 minutes. To this mixture was 
then added a master mix containing 7.6 µl of nuclease-free water, 4 l of 5x reaction buffer, 
1.5 mM MgCl2, 0.67 mM dNTPs, 20 U of recombinant RNasin® ribonuclease inhibitor, and 
160 U ImProm-II reverse transcriptase. The reaction mixture was then placed at 25C for 5 
minutes to allow for primer annealing, then at 45C for 1 hour for reverse transcription to take 
place and finally at 70C for 15 minutes to terminate the reaction by inactivating the reverse 
transcriptase enzyme. The cDNA samples were then cooled on ice and stored at -20C for 
future analysis. 
2.5 Quantitative real-time polymerase chain reaction (qPCR) 
All qPCR experiments were performed using the LightCycler 96 (Roche Applied Science) 
according to the manufacturer’s instructions. The qPCR reaction mixture contained 6.25 l of 
1x KAPA SYBR FAST qPCR Master Mix, containing all PCR reagents needed for the PCR 
including the DNA polymerase enzyme (Kapa Biosystems), 0.5 M of the respective forward 
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and reverse primers and nuclease-free water to complete the reaction mixture to 9 l per 
sample. This was then added to 1 l of cDNA or nuclease-free water (non-template control). 
The PCR conditions used were set using the LightCycler 96 software. The conditions were 
as follows: cDNA was pre-incubated at 95 °C for 3 seconds. This was followed by 
amplification which consisted of denaturation at 95 °C for 3 seconds, primer specific annealing 
temperature for 20 seconds and extension of DNA at 72 °C for 3 seconds, all repeated 45 times. 
A melting step at 95 °C for 10 seconds then followed. A 3% agarose gel was then used to verify 
the size of the product compared to a 100bp DNA ladder as the expected product size was 141 
bp (Table 2.2). This was only done for the human G6Pase gene as the rest have been verified 
previously (264). For BWTG3 samples, GAPDH was used as a reference gene and for HepG2 
samples, 18S was used as a reference gene. The mRNA levels of the gene of interest were 
normalized relative to the respective reference gene. Relative quantification of the target genes 
was performed using the comparative CT method (delta-delta CT method) with the respective 
vehicles arbitrarily set to 1. Table 2.2 shows further details specific to each primer pair. 
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Table 2.2 Human (Homo sapien) and mouse (Mus musculus) primer sequences as determined 



























90 bp 60 C 2.08 
CCTCCAATGGATCCTCGTTA Reverse 
 
2.6 Western blot analysis 
 2.6.1 Preparation of protein lysates 
After maintaining and treating cells as described in sections 2.2.1 and 2.2.2 above, the cells 
were washed with ice cold PBS.  The cells were then lysed in 100 l of passive lysis buffer ( 
0.09 M Tris pH 8.0, 0.5 M EDTA, 10% glycerol, 0.2% (v/v) TritonX-100) containing the 
following cocktail of protease and phosphatase inhibitors: phenylmethylsulfonyl fluoride 
(PMSF) – a serine protease inhibitor; sodium fluoride (NaF) – a serine/threonine protein 
phosphatase inhibitor and sodium orthovanadate (Na3VO4) – a protein tyrosine phosphatase 
inhibitor. Lysates were then transferred to clean 1.5 ml microcentrifuge tubes and 100 l of 1 
x sodium dodecyl sulphate (SDS) sample buffer (1 M Tris-HCl, pH 8.6; 10% (v/v) SDS; 0.1% 
(w/v) bromophenol blue; 2% (v/v) -mercaptoethanol and 20% (v/v) glycerol) was added to 
the lysates. Samples were then boiled for 10 minutes at 95 C to facilitate denaturation of the 
proteins. 
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 2.6.2 SDS- polyacrylamide gel electrophoresis and western blot 
Protein lysates were separated using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
a 10% SDS polyacrylamide gel. Proteins were electrophoresed at 100V for 15min and then at 
200V for 90 minutes. After electrophoresis, the proteins were transferred to 0.45M 
nitrocellulose membrane (Amersham) at 0.18 A for 2 hours. The membranes were then blocked 
for 90 minutes at room in either 5% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich) in 
tris-buffered saline (TBS, 50 mM Tris, 150 mM NaCl) containing 0.1% Tween20 (TBST) or 
5% (w/v) instant skimmed milk powder in TBST. After blocking, the membranes were then 
washed with TBST, twice for 5 minutes each, and then with TBS for 5 minutes. This was 
followed by incubation of the membrane in the appropriate primary antibodies (Cell Signalling 
Technology or Santa Cruz Biotechnology) described in Table 2.3 overnight at 4C. The 
membranes were then washed again as described above before being incubated with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (Santa Cruz 
Biotechnology or Sigma-Aldrich) diluted in 1% (w/v) BSA in TBST or 5% (w/v) instant 
skimmed milk powder in TBST, described in Table 2.3,  at room temperature for 90 minutes. 
The membranes were once again washed as described above and then visualised using 
Clarity ECL western blotting substrate (Biorad) and the Thermo Scientific MyECL imager 
(Thermo Fisher Scientific). Quantification of the bands was performed using the ImageJ 
programme (NIH) and overlaying of the blots to verify protein size was performed using 
MyImageAnalysis software (Thermo Fisher Scientific).  
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Primary antibody + catalog 
no. Dilution Secondary antibody Dilution 
Phosphorylated proteins 
Phospho – Akt (Ser 473) 
#4060 
(blocked in 5% BSA in TBST) 
1:700 
Anti-rabbit IgG A9169 
 
1:1000 
(diluted in 1% BSA in TBST) 
Phospho – Akt (Thr 308) 
#13038 
(blocked in 5% instant skimmed milk 
powder in TBST) 
1:700 
Anti-rabbit IgG A9169 
 
1:1000 
(diluted in 5% instant 









(diluted in 5% instant 






(blocked in 5% instant skimmed milk 
powder in TBST) 
1:1000 
Anti-rabbit IgG A9169 
 
1:1000 
(diluted in 5% instant 









(diluted in 5% instant 





(blocked in 5% instant skimmed milk 
powder in TBST) 
1:1000 




(diluted in 5% instant 




(blocked in 5% instant skimmed 
milk powder in TBST)  
1:5000 




(diluted in 5% instant 
skimmed milk powder in 
TBST) 
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2.7 Statistical analysis 
GraphPad Prism® version 8 was used for statistical analysis of data. Student’s t-test with 
Tukey’s Multiple Comparison’s post-test was used to compare the treatments to one another. 
Statistical significance was indicated by * where p<0.05. No statistical significance was 
indicated by (ns), where p>0.05. All data shown represents at least three independent 
experiments with error bars indicating standard error of the mean. 




CHAPTER THREE: RESULTS 
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Although glucocorticoids (GCs) and pro-inflammatory cytokines are known to antagonise each 
other’s biological function especially in regard to inflammation, both types of cell signalling 
mediators have been implicated in the development of insulin resistance and subsequent Type 
2 diabetes (T2DM) (136, 179, 268–270). Patients suffering from rheumatoid arthritis for 
example are more likely to develop insulin resistance (271). Rheumatoid arthritis is associated 
with chronic systemic inflammation characterised by high tumour necrosis factor alpha (TNF-
α) and interleukin-6 (IL-6) levels while in addition exogenous GC treatment is prescribed to 
combat inflammation (272–275). Despite the association between the development of insulin 
resistance and chronic systemic inflammation or chronic exposure to GCs, either endogenous 
or exogenous, very little is known about whether pro-inflammatory mediators such as TNF-α 
and IL-6 together with GCs affect the development of insulin resistance. It is for this reason 
that the primary aim of this study was to investigate whether GCs, dex (representing synthetic 
GCs), corticosterone (mouse endogenous GC) and cortisol (human endogenous GC), and two 
well-studied pro-inflammatory cytokines, TNF-α and IL-6, co-regulate insulin signalling. This 
was achieved by investigating the effects of the GCs at three different concentrations in the 
absence and presence of either of the two pro-inflammatory cytokines on a key node of the 
insulin signalling pathway, namely AKT. 
Total protein expression as well as activation by means of phosphorylation at the two key 
residues (threonine 308 and serine 473) of AKT were examined using western blot analysis. 
The inability of AKT to become phosphorylated in response to insulin treatment is commonly 
associated with an insulin resistant state (44, 141, 276). In addition, the effects of the selected 
GCs and pro-inflammatory cytokines on the glycogen synthesis node of the insulin signalling 
pathway was also examined. This was achieved by investigating the protein expression of 
GSK-3α and GSK-3β in response to treatment with the selected GCs, at 1 M only, in the 
absence and presence of either of the two pro-inflammatory cytokines. Additionally, the 
phosphorylation of GSK-3α and GSK-3β (tyrosine 279 for GSK-3 and tyrosine 216 for GSK-
3) was also studied in response to the test compounds. Phosphorylation of GSK-3 at tyrosine 
279 and GSK-3 at tyrosine 216 is indicative of protein stability as well as biologically active 
GSK-3, unlike phosphorylation at specific serine residues, which inhibits GSK-3 activity (49–
51, 119).  
Finally, whether GCs and the pro-inflammatory cytokines could co-regulate the inhibitory 
gluconeogenic node of the insulin signalling pathway was examined. The mRNA expression 
of glucose-6-phosphatase (G6Pase), an important gluconeogenic enzyme, was investigated in 
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response to dex, chosen as a representative GC, at three different concentrations in the absence 
and presence of either of the two pro-inflammatory cytokines.  
3.1 Effects of the test compounds on the protein expression of AKT 
AKT plays a critical role in the insulin signalling pathway. It is often thought of as the central 
node of insulin signalling from which numerous other signalling responses branch from (92) 
as indicated in Figure 1.1 (Chapter 1, section 1.3). Inhibition of insulin-induced AKT signalling 
is often associated with an insulin resistant state (44, 94, 141, 277) highlighting its importance 
when studying insulin signalling and insulin resistance. In this study 100 ng/ml insulin had no 
effect on the protein expression of total AKT in both the BWTG3 and HepG2 cell lines (Figs 
3.1A & B, 3.2A & B, 3.3A & B, 3.4A & B). Furthermore, the addition of 20 ng/ml of either 
TNF- (Figs 3.1A, 3.2A, 3.3A, 3.4A) or IL-6 (Figs 3.1B, 3.2B 3.3B, 3.4B) to the insulin 
treatment did not affect the protein expression of total AKT in both cell lines used. All 
subsequent treatments with the test compounds were done in the presence of 100 ng/ml insulin.   
In the BWTG3 cell line, the synthetic GC, dex at all the concentrations tested had no effect on 
total AKT protein expression either in the absence (Fig 3.1.C & D) or presence of TNF-α (Fig. 
3.1.C). Similarly, lower dex concentrations in the presence of IL-6 did not affect total AKT 
protein levels, however a slight but significant (p<0.05) increase was observed with 1 M dex 
in the presence of IL-6 (Fig. 3.1.D). Unlike with the synthetic GC, total AKT protein levels 
significantly (p<0.05) decreased when BWTG3 cells were treated with corticosterone in the 
absence of a pro-inflammatory cytokine (Fig 3.2.C & D). Treatment with 100 nM and 1 M 
corticosterone in the presence of TNF- however, caused a slight but significant (p<0.05) 
increase in total AKT protein expression, which was significantly (p<0.05) higher than the 
insulin only treatment (Fig 3.2.C). Unlike, TNF-, IL-6 had no significant (p>0.05) effect on 
the ability of corticosterone to decrease total AKT protein expression (Fig. 3.2.D). Total AKT 
protein levels were restored to basal levels when BWTG3 cells were co-treated with 1 M 
corticosterone and IL-6 in the presence of insulin, although the response was not significantly 
(p>0.05) different to that of 1M corticosterone alone.   
In the human hepatocyte cell line (HepG2 cells), dex significantly (p<0.05) increased total 
AKT protein expression when compared to the insulin only treatment. (Fig. 3.3C & D). In the 
presence of TNF-, there was no significant (p>0.05) difference to dex-only treatments (Fig. 
3.3.C. Dex lost its ability to increase total AKT protein levels when co-treated with IL-6 (Fig. 
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3.3D) ), with a significant (p<0.05) decrease in AKT protein levels at all concentrations of dex 
in the presence of IL-6. In contrast to dex treatment, the endogenous human GC, cortisol had 
no significant (p>0.05) effect on total AKT protein levels in the absence or presence of the pro-
inflammatory cytokines (Fig. 3.4.C & D).  
 
Figure 3.1. Dex only at the highest concentration tested in the presence of IL-6 increases total AKT protein expression 
in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 
M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of dex at the various 
concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin 
(Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Total AKT expression was measured and 
quantified using EF-11 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and all 
treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, 
D, F) Data shown represents either three or four independent experiments. Statistical analysis was performed using an unpaired 
student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents comparing 
the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no significance. 
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Figure 3.2. Corticosterone at high concentrations in the presence of TNF- increases total AKT expression in BWTG3 
cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 M 
corticosterone (Cort), or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of 
corticosterone at the various concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated 
with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Total AKT expression was 
measured and quantified using EF-11 as the loading control. The response of insulin was set to 1 (represented by the dotted 
line) and all treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) 
and IL-6 (B, D, F) Data shown represents either three or four independent experiments. Statistical analysis was performed 
using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) 
represents comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents 
no significance. 
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Figure 3.3. IL-6 antagonises dex-induced increase of total AKT in HepG2 cells. HepG2 cells were serum starved for 
24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 M dex, or 20 ng/ml of either TNF- or IL-6. For co-
treatments, cells were treated with a combination of dex at the various concentrations and either of the two cytokines. This 
was done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin 
signalling pathway. Total AKT expression was measured and quantified using EF-11 as the loading control. The response of 
insulin was set to 1 (represented by the dotted line) and all treatments were normalised to this insulin control. Images are 
separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, D, F). Statistical analysis was performed using an unpaired 
student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents comparing 
the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no significance. 
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Figure 3.4. Cortisol in the absence or presence of TNF- or IL-6 has no effect on total AKT expression levels in HepG2 
cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 M cortisol 
(F), or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of cortisol at the various 
concentrations and either of the two cytokines. This was done for 24 hours. Cells were subsequently treated with 100 ng/ml 
insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Total AKT expression was measured and 
quantified using EF-11 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and all 
treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, 
D, F). Statistical analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to the 
insulin control only whilst # (p<0.05) represents comparing the GC treatment in the absence and presence of the pro-
inflammatory cytokine; ns (p>0.05) represents no significance. 
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3.2 Effects of the test compounds on phosphorylation of AKT at threonine 
308. 
Stimulation of the insulin signalling pathway leads to the phosphorylation of two critical 
residues belonging to AKT, with threonine 308, in the activation or T-loop being the first 
residue phosphorylated (92). Phosphorylation of threonine 308 is crucial for the catalytic 
activity of AKT (278). Failure to phosphorylate the enzyme for whatever reason, results in the 
inhibition of insulin-induced activation of AKT (44, 279). 
In the absence of insulin, no phosphorylation of AKT at threonine 308 was observed 
(Fig. 3.5E & F).  Exposure to 100 ng/ml insulin for 30 minutes significantly (p<0.05) increased 
the phosphorylation of AKT at threonine 308 between 7- and 17-fold in the BWTG3 and 
HepG2 cell lines, respectively (Figs. 3.5A & B, 3.6A & B, 3.7A & B, 3.8A & B).  The pro-
inflammatory cytokines TNF- and IL-6 had no effect on the insulin-induced phosphorylation 
of AKT at threonine 308 in both hepatocyte cell models (Figs. 3.5A & B, 3.6A & B, 3.7A & 
B, 3.8A & B).  
Treatment with dex in the absence and presence of the pro-inflammatory cytokines, TNF-α and 
IL-6, did not influence the ability of insulin to induce phosphorylation of AKT at threonine 
308 in the BWTG3 cells (Fig. 3.5C - F). Similarly, corticosterone alone at the lower 
concentrations tested (10 nM and 100 nM) did not significantly (p>0.05) affect the insulin-
induced phosphorylation of AKT at threonine 308. In contrast, 1 M corticosterone 
significantly (p<0.05) decreased insulin-induced phosphorylation of AKT at threonine 308 in 
BWTG3 cells (Fig. 3.6C & D). Corticosterone at concentrations 10 nM and 1 M in the 
presence of 20 ng/ml TNF- significantly (p<0.05) increased the phosphorylation of AKT at 
threonine 308 in BWTG3 cells compared to corticosterone alone, although this was not 
significantly (p>0.05) different to the insulin only treatment (Fig. 3.6C). In contrast, 1 M 
corticosterone in the presence of IL-6 significantly (p<0.05) augmented the insulin-induced 
phosphorylation of AKT at threonine 308. IL-6 co-treated with the lower concentrations of 
corticosterone, 10 nM and 100 nM, however, did not affect insulin-induced phosphorylation of 
AKT at threonine 308 (Fig. 3.6D). 
In contrast to the BWTG3 cells, in the HepG2 cell line, dex at all concentrations tested 
significantly (p<0.05) increased the insulin-induced phosphorylation, which was unaffected by 
the pro-inflammatory cytokines, TNF-α and IL-6 (Fig. 3.7C-F). Unlike dex, the endogenous 
GC, cortisol, in the absence and presence of TNF-α did not affect the insulin-induced 
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phosphorylation of AKT at threonine 308 (Fig. 3.8C & E). Similarly, IL-6 in the presence of 
cortisol had no significant (p>0.05) effect on the insulin-induced phosphorylation of AKT at 
threonine 308 (Fig. 3.8.D & F) except for 100 nM cortisol where the presence of IL-6 caused 
a decrease in phosphorylation. A significant (p<0.05) decrease in the insulin-induced 
phosphorylation of AKT at threonine 308 was observed when the HepG2 cells were treated 
with 100 nM cortisol in the presence of 20 ng/ml IL-6 compared to 100 nM cortisol treatment 
alone. This decrease in phosphorylation of AKT at threonine 308 when HepG2 cells were co-
treated with 100 nM cortisol and IL-6 was also significantly (p<0.05) different to the insulin 
only treatment (Fig. 3.8.D).




Figure 3.5 Dex in the absence and presence of TNF- or IL-6 does not affect the insulin-induced phosphorylation of 
AKT at threonine 308 (T308) in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were 
treated with 10 nM, 100 nM or 1 M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a 
combination of dex at the various concentrations and either of the two cytokines. This was done for 24 hours. Cells were then 
treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Phospho-Akt 
(T308) expression was measured and quantified using EF-11 as the loading control. The response of insulin was set to 1 
(represented by the dotted line) and all treatments were normalised to this insulin control. Images are separated by cytokine 
type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown represents either three or four independent experiments. Statistical 
analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control; ns 
(p>0.05) represents no significance. 




Figure 3.6 IL-6 co-operatively increases the insulin-induced phosphorylation of AKT at threonine 308 (T308) seen at 
high concentration of corticosterone tested in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the 
cells were treated with 10 nM, 100 nM or 1 M corticosterone (Cort), or 20 ng/ml of either TNF- or IL-6. For co-treatments, 
cells were treated with a combination of corticosterone at the various concentrations and either of the two cytokines. This was 
done for 24 hours. Cells were then treated with 100 ng/ml insulin for 30 minutes before lysis to stimulate the insulin signalling 
pathway. Phospho-Akt (T308) expression was measured and quantified using EF-11 as the loading control. The response of 
insulin was set to 1 (represented by the dotted line) and all treatments were normalised to this insulin control. Images are 
separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown represents either three or four independent 
experiments. Statistical analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to 
the insulin control only whilst # (p<0.05) represents comparing the GC treatment in the absence and presence of the pro-
inflammatory cytokine; ns (p>0.05) represents no significance. 




Figure 3.7 Treatment with dex in the absence and presence of TNF- or IL-6 significantly increase the insulin-induced 
phosphorylation of AKT at threonine 308 (T308) in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter 
the cells were treated with 10 nM, 100 nM or 1 M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were 
treated with a combination of dex at the various concentrations and either of the two cytokines. This was done for 24 hours. 
Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. 
Phospho-Akt (T308) expression was measured and quantified using EF-11 as the loading control. The response of insulin 
was set to 1 (represented by the dotted line) and all treatments were normalised to this insulin control. Images are separated 
by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown represents either three or four independent experiments. 
Statistical analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin 
control; ns (p>0.05) represents no significance. 




Figure 3.8 Cortisol only at 100 nM in the presence of IL-6 decreased insulin-induced phosphorylation of AKT at 
threonine 308 (T308) in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated with 
10 nM, 100 nM or 1 M cortisol (F), or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a 
combination of cortisol at the various concentrations and either of the two cytokines. This was done for 24 hours. Cells were 
then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Phospho-Akt 
(T308) expression was measured and quantified using EF-11 as the loading control. The response of insulin was set to 1 
(represented by the dotted line) and all treatments were normalised to this insulin control. Images are separated by cytokine 
type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown represents either three or four independent experiments. Statistical 
analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only 
whilst # (p<0.05) represents comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns 
(p>0.05) represents no significance. 
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3.3 Effects of the test compounds on phosphorylation of AKT at serine 473 
The second critical residue of AKT to be phosphorylated is serine 473 situated in the 
hydrophobic domain of the enzyme (278). Phosphorylation of this residue further augments 
the enzymatic activity of AKT and expands its substrate scope (278).  Due to the limit of 
detection little to no phosphorylation of AKT at serine 473 was observed in the absence of 
insulin in both hepatocyte cell models (Figs. 3.9A & B, 3.10A & B, 3.11A & B, 3.12A & B), 
similar to what was observed with threonine 308 AKT phosphorylation (Figs. 3.5A & B, 3.6A 
& B, 3.7A & B, 3.8A & B). Treatment with 100 ng/ml insulin resulted in a significant (p<0.05) 
increase of phosphorylated AKT at serine 473 in both cell lines used (Fig. 3.9A & B, 3.10A & 
B, 3.11A & B, 3.12A & B). TNF- and IL-6, like with threonine 308 AKT phosphorylation, 
had no significant (p>0.05) effect on insulin-induced phosphorylation of AKT at serine 473 
(Fig. 3.9A & B, 3.10A & B, 3.11A & B, 3.12A & B).  
Dex treatment alone did not affect the insulin-induced phosphorylation of AKT at serine 473 
(Fig. 3.9C & D) in the murine BWTG3 cells. However, in the presence of TNF-α, 10 nM and 
100 nM dex significantly (p<0.05) increased the insulin-induced AKT phosphorylation at 
serine 473. This increase in serine 473 phosphorylation of AKT however, is absent when TNF-
α is co-treated with the highest concentration of dex (1 M) used (Fig. 3.9.C). In contrast, only 
100 nM dex in the presence of IL-6 significantly (p<0.05) increased insulin-induced serine 473 
phosphorylation of AKT compared to insulin in the absence and presence of 100 nM dex. Co-
treatment with IL-6 and 10 nM or 1 M dex had no significant (p>0.05) effect on the 
phosphorylation status of AKT at serine 473 compared to insulin alone or insulin in the 
presence of dex only (Fig. 3.9D). Corticosterone treatment had no significant (p>0.05) effect 
on insulin-induced serine 473 phosphorylation of AKT except for 1 M corticosterone in 
BWTG3 cells (Fig. 3.10C & D).  Although 100 nM corticosterone did not affect the insulin-
induced phosphorylation of AKT at serine 473, in the presence of 20 ng/ml TNF- insulin-
induced phosphorylation of this serine residue significantly (p<0.05) increased in BWTG3 
cells. Furthermore, the significant (p<0.05) increase in insulin-induced AKT phosphorylation 
by 1 M corticosterone is potentiated by co-treating with TNF-α (Fig. 3.10C & E). In contrast, 
the increase in insulin-induced serine 473 phosphorylation of AKT in BWTG3 cells by 1 M 
corticosterone was significantly (p<0.05) attenuated when co-treated with IL-6. This decrease 
in phosphorylation, however, is not significantly (p>0.05) different from the insulin only 
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treatment. In addition, IL-6 had no significant (p>0.05) effect on lower concentrations (10 nM 
and 100nM) of corticosterone treatment Fig. 3.10D & F).  
In the HepG2 cells, similar to the BWTG3 cells, dex treatment augmented insulin-induced 
phosphorylation of AKT at serine 473 (Fig. 3.11C & D). This increased response, however, 
was significantly (p<0.05) inhibited by TNF-α when co-treated with 100 nM dex, although the 
response remained significantly different from the insulin-only induced AKT phosphorylation 
at serine 473. Furthermore, although significance could not be established, TNF-α was also 
able to inhibit 10 nM dex to an extent similar to the insulin only treatment. In contrast, TNF-α 
significantly (p<0.05) enhanced the effect of the highest concentration (1 M) dex tested on 
insulin-induced phosphorylation of AKT at serine 473 (Fig. 3.11C & E). Similarly, IL-6 in the 
presence of 1 M dex significantly (p<0.05) increased insulin-induced phosphorylation of 
AKT at serine 473 compared to 1 M dex treatment. In contrast, IL-6 in the presence of the 
lower dex concentrations (10 nM and 100 nM), significantly (p<0.05) attenuated the increase 
in insulin-induced serine 473 phosphorylation of AKT mediated by dex, however, only IL-6 
co-treated with 10 nM dex resulted in a phosphorylation status of AKT at serine 473 similar to 
the insulin treatment alone (Fig. 3.11D & F).   In contrast to the synthetic GC treatment studies, 
insulin induced AKT phosphorylation at serine 473 was only significantly (p<0.05) affected 
by the highest concentration (1 M) of cortisol investigated (Fig. 3.12). The effect of 1 M 
cortisol on insulin-induced phosphorylation of AKT at serine 473 is significantly (p<0.05) 
inhibited by TNF-α to similar levels of that induced by insulin alone (Fig. 3.12C & E). Unlike 
TNF-α, co-treatment with IL-6 did not influence the effect of cortisol on insulin-induced AKT 
serine 473 phosphorylation (Fig. 3.12D & F).  
 




Figure 3.9 Dex and the cytokines exhibit co-operative effects on insulin-induced phosphorylation of AKT at serine 473 
in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 
M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of dex at the various 
concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin 
(Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Phospho-Akt (S473) expression was measured 
and quantified using EF-11 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and 
all treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 
(B, D, F). Data shown represents either three or four independent experiments. Statistical analysis was performed using an 
unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents 
comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no 
significance. 




Figure 3.10 TNF- and IL-6 exhibit different effects in the presence of corticosterone on insulin-induced 
phosphorylation of AKT at serine 473 in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells 
were treated with 10 nM, 100 nM or 1 M corticosterone (Cort), or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells 
were treated with a combination of corticosterone at the various concentrations and either of the two cytokines. This was done 
for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling 
pathway. Phospho-Akt (S473) expression was measured and quantified using EF-11 as the loading control. The response of 
insulin was set to 1 (represented by the dotted line) and all treatments were normalised to this insulin control. Images are 
separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, D, F). Data shown represents either three or four independent 
experiments. Statistical analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to 
the insulin control only whilst # (p<0.05) represents comparing the GC treatment in the absence and presence of the pro-
inflammatory cytokine; ns (p>0.05) represents no significance. 
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Figure 3.11 TNF- and IL-6 in the presence of dex exhibit similar effects on insulin-induced phosphorylation of AKT 
at serine 473 (S473) in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 
nM, 100 nM or 1 M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of 
dex at the various concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated with 100 
ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Phospho-Akt (S473) expression was 
measured and quantified using EF-11 as the loading control. The response of insulin was set to 1 (represented by the dotted 
line) and all treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) 
and IL-6 (B, D, F) Data shown represents either three or four independent experiments. Statistical analysis was performed 
using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) 
represents comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents 
no significance. 
 




Figure 3.12 TNF- alone antagonises the insulin-induced phosphorylation of AKT at serine 473 (S473) seen at high 
concentrations of cortisol in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated 
with 10 nM, 100 nM or 1 M cortisol (F), or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a 
combination of cortisol at the various concentrations and either of the two cytokines. This was done for 24 hours. Cells were 
then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. Phospho-Akt 
(S473) expression was measured and quantified using EF-11 as the loading control. The response of insulin was set to 1 
(represented by the dotted line) and all treatments were normalised to this insulin control. Images are separated by cytokine 
type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown represents either three or four independent experiments. Statistical 
analysis was performed using an unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only 
whilst # (p<0.05) represents comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns 
(p>0.05) represents no significance 
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3.4 Effects of the test compounds on GSK-3 protein expression 
As described in chapter one (section 1.3.3) glycogen synthesis is regulated by GSK-3. In 
resting cells, GSK-3 phosphorylates GS, thereby inactivating it, which results in the inhibition 
of glycogen synthesis (50, 121, 280). Phosphorylation of GSK-3α and GSK-3β at tyrosine 279 
and tyrosine 216, respectively is required for maximal GSK-3 activity (51).   
Treatment with 100 ng/ml insulin in the absence and presence of 20 ng/ml of either TNF- or 
IL-6 did not affect the protein expression of either GSK-3 (Fig. 3.13A & B) or GSK-3 (Fig. 
3.13C & D) in the BWTG3 cells. 
In the absence and presence of either of the pro-inflammatory cytokines, neither dex nor 
corticosterone affected the protein expression of GSK-3 in BWTG3 cells in comparison to 
the insulin only treatment (which was set to 1), except for the co-treatment of 1 µM dex with 
IL-6 which decreased GSK-3 protein levels, however, not significantly (p>0.05) compared 
to 1 µM dex alone (Fig. 3.14A & B). In contrast, 1 µM dex and corticosterone significantly 
(p<0.05) increased GSK-3 protein levels in BWTG3 cells that was unaffected by co-treating 
with 20 ng/ml TNF- (Fig. 3.14C). Unlike co-treatment with TNF-, IL-6 attenuated the 
increase in GSK-3 protein levels induced by both GCs in BWTG3 cells although significance 
could only be established for the co-treatment with the endogenous GC, corticosterone. 
Specifically, corticosterone-induced GSK- protein expression was significantly (p<0.05) 
attenuated by 20 ng/ml IL-6 to an extent significantly (p<0.05) lower than basal levels (insulin 
only treatment) (Fig. 3.14D).  
In the HepG2 cell line, like with the BWTG3 cells, 100 ng/ml insulin treatment in the absence 
and presence of 20 ng/ml of either TNF- or IL-6 had no effect on GSK-3 (Fig. 3.15A & B) 
or GSK-3 (Fig. 3.15C & D) protein expression. Similarly, GSK-3α protein expression was 
not affected by either dex or cortisol in the absence and presence of either of the pro-
inflammatory cytokines (Fig. 3.16A & B). Whilst both the exogenous and endogenous GCs 
affected GSK-3β protein expression in the mouse hepatocyte cell line, in the HepG2 cells only 
the endogenous GC, cortisol, significantly (p<0.05) increased GSK-3β protein expression (Fig. 
3.16C & D). Like with the BWTG3 cell line, only IL-6, and not TNF-α, was able to attenuate 
the cortisol-induced increase in GSK-3β protein expression (Fig. 3.16C).  
  




Figure 3.13. Neither insulin nor the cytokines affect GSK-3 protein expression in the BWTG3 cell line. BWTG3 cells 
were serum starved for 24 hours. Thereafter the cells were treated 20 ng/ml of either TNF- or IL-6. This was done for 24 
hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling 
pathway. GSK-3 (A, B) and GSK-3 (C, D) expression was measured and quantified using HSP90 as the loading control. 
Images are separated by cytokine type, i.e TNF- (A, C) and IL-6 (B, D) Data shown represents between three and five 
independent experiments. Statistical analysis comparing the treatment conditions to one another was performed using an 
unpaired student’s t-test; ns (p>0.05) represents no significance. 




Figure 3.14. IL-6 antagonised the corticosterone-induced increase in GSK-3 in BWTG3 cells. BWTG3 cells were serum 
starved for 24 hours. Thereafter the cells were treated with 1 M dex or corticosterone (cort), in the absence or presence of 20 
ng/ml of either TNF- or IL-6. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes 
before lysis to stimulate the insulin signalling pathway. GSK-3 (A, B) and GSK-3 (C, D) expression was measured and 
quantified using HSP90 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and all 
treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, 
D, F) Data shown represents between three and five independent experiments. Statistical analysis was performed using an 
unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents 
comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no 
significance. 





Figure 3.15. Neither insulin nor the cytokines affect the protein expression of GSK-3 in the HepG2 cell line. HepG2 cells 
were serum starved for 24 hours. Thereafter the cells were treated 20 ng/ml of either TNF- or IL-6. This was done for 24 
hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling 
pathway. GSK-3 (A, B) and GSK-3 (C, D) expression was measured and quantified using HSP90 as the loading control. 
Images are separated by cytokine type, i.e TNF- (A, C) and IL-6 (B, D) Data shown represents between three and five 
independent experiments. Statistical analysis comparing the treatment conditions to one another was performed using an 
unpaired student’s t-test; ns represents no significance. 




Figure 3.16. IL-6 but not TNF- antagonises the cortisol-induced increase in GSK-3 expression in HepG2 cells. HepG2 
cells were serum starved for 24 hours. Thereafter the cells were treated with 1 M dex or cortisol (F), in the absence or presence 
of 20 ng/ml of either TNF- or IL-6. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 
minutes before lysis to stimulate the insulin signalling pathway. GSK-3 (A, B) and GSK-3 (C, D) expression was measured 
and quantified using HSP90 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and 
all treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 
(B, D, F) Data shown represents between three and five independent experiments. Statistical analysis was performed using an 
unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents 
comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no 
significance. 
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3.5 Effects of the test compounds on the tyrosine phosphorylation of GSK-3 
In resting cells, GSK-3 is basally active and highly phosphorylated at key tyrosine residues 
(Tyr 279 on GSK-3 and Tyr 216 on GSK-3) (51, 281, 282). Phosphorylation of GSK-3 at 
these residues increase the kinase activity of the enzyme, without which the kinase activity of 
GSK-3 would be impaired (49). 
Insulin (100 ng/ml) in the absence and presence of 20 ng/ml of either TNF- or IL-6 had no 
effect on the phosphorylation of either GSK-3 at tyrosine 279 (Fig. 3.17A & B) or GSK-3 
at tyrosine 216 (Fig. 3.17C & D) in BWTG3 cells. All treatment with the GCs and the pro-
inflammatory cytokines were done in the presence of insulin with phosphorylation of 
tyrosine 279 of GSK-3 or at tyrosine 216 of GSK-3β in the presence of insulin alone set as 1 
for analysis. 
Dex in the absence and presence of 20 ng/ml of either of the pro-inflammatory cytokines did 
not affect tyrosine 279 phosphorylation of GSK-3 (Fig 3.18A & B). In contrast, 1M 
corticosterone significantly (p<0.05) decreased GSK-3 phosphorylation at tyrosine 279 (Fig. 
3.18A & B), which was then only attenuated significantly (p<0.05) by IL-6 (Fig. 3.18B), but 
not TNF- (Fig. 3.18A), although it did increase GSK-3 phosphorylation at tyrosine 279 to 
levels similar to that of the cells stimulated with insulin only i.e., basal levels.   
Similar to GSK-3 phosphorylation at tyrosine 279, 1 M dex alone had no significant 
(p>0.05) effect on GSK-3 phosphorylation at tyrosine 216 (Fig. 3.18C & D). However, dex 
in the presence of 20 ng/ml TNF- significantly (p<0.05) increased phosphorylation of GSK-
3 at tyrosine 216 when compared to insulin only treatment, although it was not statistically 
different from dex treatment alone (Fig. 3.18C). In contrast, 1 M dex in the presence of 20 
ng/ml IL-6 significantly (p<0.05) decreased the tyrosine 216 phosphorylation of GSK-3 
compared to insulin in the absence and presence of dex (Fig. 3.18D). Unlike dex, 1 M 
corticosterone significantly (p<0.05) decreased the tyrosine 216 phosphorylation of GSK-3 
compared to insulin, which was inhibited by the pro-inflammatory cytokines although only 
significantly (p<0.05) for IL-6 (Fig. 3.18C & D). Although 20 ng/ml TNF- was unable to 
significantly (p>0.05) inhibit corticosterone, it did restore phosphorylation of GSK-3 at 
tyrosine 216 to basal levels and similar to cells treated with insulin only (Fig. 3.18C).   
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Similar to the mouse cell line, HepG2 cells treated with 100 ng/ml insulin in the absence or 
presence of 20 ng/ml TNF- or IL-6 did not significantly (p>0.05) affect the phosphorylation 
of either GSK-3 at tyrosine 279 (Fig. 3.19A & B) or GSK-3 at tyrosine 216 (Fig. 3.19C & 
D). 
Dex at a concentration of 1M in the absence of the pro-inflammatory cytokines did not affect 
tyrosine 279 phosphorylation of GSK-3 (Fig. 3.20A & B). However, dex co-treatment with 
either of the pro-inflammatory cytokines significantly (p<0.05) increased GSK-3 
phosphorylation at tyrosine 279 (Fig. 3.20A & B). Unlike dex, 1M cortisol in the absence of 
the pro-inflammatory cytokines significantly (p<0.05) increased the tyrosine 279 
phosphorylation of GSK-3 compared to insulin only treatment. The addition of 20 ng/ml 
TNF- potentiated the cortisol-induced increase in tyrosine 279 phosphorylation of GSK-
3 (Fig. 3.20A), whilst 20 ng/ml IL-6 had no effect on the ability of cortisol to increase tyrosine 
279 phosphorylation of GSK-3. Thus, while both pro-inflammatory cytokines significantly 
(p<0.05) affected dex treatment, only TNF- significantly (p<0.05) affected cortisol treatment 
(Fig. 3.20A & B).     
Like with GSK-3 phosphorylation at tyrosine 279, 1 M dex in the absence of the pro-
inflammatory cytokines did not affect tyrosine 216 phosphorylation of GSK-3 (Fig. 3.20C & 
D). Co-treatment with TNF- or IL-6 however did result in a significant (p<0.05) increase in 
GSK-3 phosphorylation at tyrosine 216, when compared to insulin only treatment as well as 
to dex only (Fig. 3.20C & D). Similar to the tyrosine 279 phosphorylation of GSK-3, 1 M 
cortisol in the absence of a pro-inflammatory cytokine increased tyrosine 216 phosphorylation 
of GSK-3 when compared to insulin only treatment (Fig. 3.20C & D). In addition, like with 
GSK-3 phosphorylation at tyrosine 279, TNF- and not IL-6 was able to potentiate cortisol-
induced GSK-3β phosphorylation at tyrosine 216 (Fig. 3.20C & D), thus, again highlighting 
differential effects of the two pro-inflammatory cytokines when co-treated with the 
endogenous GC. 
 




Figure 3.17. Neither insulin nor the cytokines affect the tyrosine phosphorylation of GSK-3 in the BWTG3 cell line. 
BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated 20 ng/ml of either TNF- or IL-6. This was 
done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin 
signalling pathway. Tyrosine phosphorylation of GSK-3 (Tyr279) (A, B) and GSK-3 (Tyr216) (C, D) was measured and 
quantified using HSP90 as the loading control. Images are separated by cytokine type, i.e TNF- (A, C) and IL-6 (B, D) Data 
shown represents between three and five independent experiments. Statistical analysis comparing the treatment conditions to 
one another was performed using an unpaired student’s t-test; ns (p>0.05) represents no significance. 




Figure 3.18. Corticosterone decreased GSK-3 and GSK-3 phosphorylation, with only IL-6 displaying antagonistic 
behaviour in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated with 1 M dex 
(dex) or corticosterone (cort), in the absence or presence of 20 ng/ml of either TNF- or IL-6. This was done for 24 hours. 
Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. 
Tyrosine phosphorylation of GSK-3 (Tyr279) (A, B) and GSK-3 (Tyr216) (C, D) was measured and quantified using 
HSP90 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and all treatments were 
normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, D, F) Data shown 
represents between three and five independent experiments. Statistical analysis was performed using an unpaired student’s t-
test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents comparing the GC 
treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no significance. 




Figure 3.19. Neither insulin nor the cytokines affect the tyrosine phosphorylation of GSK-3 in the HepG2 cell line. 
HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated 20 ng/ml of either TNF- or IL-6. This was 
done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin 
signalling pathway. Tyrosine phosphorylation of GSK-3 (Tyr279) (A, B) and GSK-3 (Tyr216) (C, D) was measured and 
quantified using HSP90 as the loading control. Images are separated by cytokine type, i.e TNF- (A, C) and IL-6 (B, D) Data 
shown represents between three and five independent experiments. Statistical analysis was performed using an unpaired 
student’s t-test; ns represents no significance. 




Figure 3.20. TNF- displays co-operative behaviour in the presence of both dex and cortisol, increasing 
phosphorylation of GSK- and GSK-3 in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells 
were treated with 1 M dex or corticosterone (cort), in the absence or presence of 20 ng/ml of either TNF- or IL-6. This was 
done for 24 hours. Cells were then treated with 100 ng/ml insulin (Ins) for 30 minutes before lysis to stimulate the insulin 
signalling pathway. Tyrosine phosphorylation of GSK-3 (Tyr279) (A, B) and GSK-3 (Tyr216) (C, D) was measured and 
quantified using HSP90 as the loading control. The response of insulin was set to 1 (represented by the dotted line) and all 
treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (A, C, E) and IL-6 (B, 
D, F) Data shown represents between three and five independent experiments. Statistical analysis was performed using an 
unpaired student’s t-test with * (p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents 
comparing the GC treatment in the absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no 
significance. 
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3.6 Effects of the test compounds on the mRNA expression of G6Pase 
G6Pase plays an important role in both gluconeogenesis and glycogenolysis as both metabolic 
pathways produce its substrate, glucose-6-phosphate (283). This key metabolic enzyme thus 
affects blood glucose homeostasis through the hydrolysis of glucose-6-phosphate producing 
glucose, which can enter into the blood (110). For this reason, the effect of the synthetic 
glucocorticoid dex in the absence and presence of the pro-inflammatory cytokines on G6Pase 
mRNA expression was investigated in hepatoma cell lines stimulated with insulin for 30 
minutes.  
In the murine BWTG3 cell line, stimulation with 100 ng/ml insulin for 30 minutes in the 
absence of pro-inflammatory cytokine treatment did not affect G6Pase mRNA expression. 
Similarly, in the presence of 20 ng/ml TNF-, no change in the mRNA expression of G6Pase 
was observed. In contrast, insulin in the presence of 20 ng/ml IL-6 significantly (p<0.05) 
decreased G6Pase mRNA expression (Fig. 3.21.A). 
Dex, only at the lowest concentration tested (10 nM) and in the absence of pro-inflammatory 
cytokine treatment, significantly (p<0.05) increased G6Pase mRNA levels. No significant 
(p>0.05) change in the mRNA expression of G6Pase was observed in response to higher dex 
(100 nM and 1 µM) treatment (Fig. 3.21.B & C).  
TNF- (20 ng/ml) significantly (p<0.05) inhibited the induction of G6Pase mRNA in response 
to 10 nM dex by 3-fold (Fig. 3.21.B). However, at the higher concentrations of dex, the 
presence of 20 ng/ml TNF- did not significantly (p>0.05) change the mRNA expression of 
G6Pase compared to dex only treatment (Fig. 3.21.B). 
Whilst 20 ng/ml IL-6 had no significant (p>0.05) effect on dex treatment at all three 
concentrations tested in BWTG3 cells, a slight decrease in G6Pase mRNA levels was observed 
with 10 nM dex treatment to levels not statistically different from basal levels (Fig. 3.21.C). 
Unlike with the BWTG3 cells, treatment of the HepG2 cells with 100 ng/ml insulin for 30 
minutes resulted in a significant (p<0.05) decrease in G6Pase mRNA levels (Fig. 3.22A). The 
insulin-mediated reduction in G6Pase mRNA expression was opposed in the presence of 20 
ng/ml of TNF- or IL-6 (Fig. 3.22.A) 
Dex, at all three concentrations tested, significantly (p<0.05) increased G6Pase mRNA 
expression in the HepG2 cell line thereby opposing the insulin-induced repression of G6Pase 
mRNA levels (Fig. 3.22. B & C). The addition of 20 ng/ml TNF- was only able to antagonise 
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the effect of 10 nM dex, whilst at higher dex concentrations (100 nM and 1 µM) it was unable 
to prevent the dex-induced increase in G6Pase mRNA levels, although levels induced by co-
treatment with TNF- at high dex concentrations was also not significantly (p>0.05) different 
to that of insulin only treatment (Fig. 3.22.B). In contrast to TNF-, IL-6 had no significant 
(p>0.05) effect on dex-induced increase G6Pase mRNA levels at all concentrations tested. 
However, like with TNF- co-treatment, G6Pase mRNA levels in response to 100nM- and 
1uM dex in the presence of IL-6 was not statistically different to the insulin only treatment 
(Fig. 3.22C).  
  




Figure 3.21. TNF- antagonised dex-induced increase of G6Pase mRNA expression only at low concentrations of dex 
in BWTG3 cells. BWTG3 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 
M dex, or 20 ng/ml of either TNF- or IL-6. For co-treatments, cells were treated with a combination of dex at the various 
concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin 
(Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. G6Pase mRNA expression was measured and 
normalised using GAPDH as the housekeeping gene. The response of insulin was set to 1 (represented by the dotted line) and 
all treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF- (B) and IL-6 (C) Data 
shown represents three independent experiments. Statistical analysis was performed using an unpaired student’s t-test with * 
(p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents comparing the GC treatment in the 
absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no significance. 




Figure 3.22. TNF-a antagonised dex-induced increase of G6Pase mRNA expression only at low concentrations of dex 
in HepG2 cells. HepG2 cells were serum starved for 24 hours. Thereafter the cells were treated with 10 nM, 100 nM or 1 M 
dex, or 20 ng/ml of either TNF-a or IL-6. For co-treatments, cells were treated with a combination of dex at the various 
concentrations and either of the two cytokines. This was done for 24 hours. Cells were then treated with 100 ng/ml insulin 
(Ins) for 30 minutes before lysis to stimulate the insulin signalling pathway. G6Pase mRNA expression was measured and 
normalised using 18S as the housekeeping gene. The response of insulin was set to 1 (represented by the dotted line) and all 
treatments were normalised to this insulin control. Images are separated by cytokine type, i.e TNF-a (B) and IL-6 (C) Data 
shown represents three independent experiments. Statistical analysis was performed using an unpaired student’s t-test with * 
(p< 0.05) representing comparison to the insulin control only whilst # (p<0.05) represents comparing the GC treatment in the 
absence and presence of the pro-inflammatory cytokine; ns (p>0.05) represents no significance. 
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CHAPTER FOUR: DISCUSSION & 
CONCLUSIONS 





In recent years, diabetes has become a huge threat to global health and a burden on healthcare 
systems (284).  
The liver is an important organ, which releases glucose into circulation in the absence of 
insulin, however, in the presence of insulin, de novo glucose synthesis is halted and available 
glucose stored in the form of glycogen (107). Decreased inhibition of hepatic glucose 
production due to insulin resistance is a key contributing factor to the development and 
progression of T2DM, which accounts for over 90% of all diabetes cases worldwide (285–
287). Hepatic insulin resistance can be described as the decreased sensitivity of the liver to 
insulin, leading to hepatic glucose production and consequently hyperglycaemia, both key 
features of diabetes mellitus (10, 11, 288). Many factors have been linked to the aetiology of 
insulin resistance. These include a chronic stressed state (represented by an increase in either 
endogenous or exogenous GCs) (9, 16, 17) as well as a chronic inflammatory state (9, 18, 21). 
The fact that these two events serve opposing primary functions in the body, yet still result in 
a similar fate, lead us to question whether the biological mediators responsible for these 
processes (GCs and pro-inflammatory cytokines) are able to co-regulate the insulin signalling 
pathway. 
As mentioned, in Chapter 1 (section 1.1), the insulin signalling pathway plays an important 
role in the development of insulin resistance. It has been established that changes in the 
expression and phosphorylation state of any of the key nodes can act as contributing factors (6, 
10–15). For the purpose of this study, the key node under investigation was the signalling 
protein AKT and its downstream target GSK-3, which is involved in glycogen synthesis. 
Furthermore, the mRNA expression of a key gluconeogenic enzyme, G6Pase was also 
investigated. In order to investigate co-regulation, the effects of the test compounds on their 
own in the presence of insulin had to be measured to establish baselines to which co-treatment 
of a GC with a pro-inflammatory cytokine could be compared. 
4.2 Effects of the test compounds on the protein expression and activation of 
AKT 
The PI3K/AKT pathway plays a critical role in normal metabolism. AKT serves as the central 
protein in the pathway, controlling the regulation of a number of metabolic processes including 
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hepatic glucose production, glycogenolysis, glycogen synthesis as well as fatty acid synthesis 
(141, 289). The expression and regulation of this serine/threonine kinase is critical to the 
functioning of the metabolic branch of the insulin signalling pathway (141). Loss of or 
deactivating of this protein leads to reduced insulin signalling capacity and ultimately results 
in obesity, insulin resistance, and finally T2DM (141, 290). For this reason, the current study 
looked at the protein expression as well as regulatory phosphorylation of AKT in response to 
co-treatment with GCs and a pro-inflammatory cytokine. 
4.2.1 AKT protein expression 
The total AKT protein levels are directly correlated to the amplification of the downstream 
signalling of the insulin signalling pathway. Influencing the levels of AKT will influence the 
extent of insulin signal transduction and as a result the progression to an insulin resistant state. 
In the current study, the pro-inflammatory cytokines did not influence the inability of insulin 
to affect total AKT protein levels in both the murine and human hepatoma cell lines (Figs 3.1A 
& B and 3.2 A & B). Similarly, a study conducted by Osawa, et al., showed by western blotting 
that treatment of hepatocytes with 20 ng/ml TNF-, did not affect AKT protein levels, although 
this was in the absence of insulin (291). In contrast, another study observed, also using western 
blotting, that HepG2 cells treated with 20 ng/ml IL-6 in the presence of either 0.5 nM or 
100 nM insulin exhibited increased total AKT protein expression, which appeared to be time 
dependent although the western blots were not quantified and only one representative figure 
was shown (34). Similarly, Kim JH et al., also using HepG2 cells and western blotting, which 
was not quantified, demonstrated that insulin slightly decreased total AKT expression, which 
was restored by IL-6 to that of basal AKT protein levels (292). These studies used a similar 
IL-6 concentration to that of the current study (20ng/ml) however, the maximum treatment 
time with IL-6 reported, was much shorter (between 1 and 8 hours) compared to the 24 hrs 
treatment of the current study. This might suggest that the effect of IL-6 on AKT might be time 
sensitive and that recovery of affected AKT expression is quickly restored to basal levels, 
although this hypothesis requires further investigation.  
Unlike for the pro-inflammatory cytokines, the effect on AKT expression by the GCs appeared 
to be cell line dependent, in addition to the type of GC used i.e., natural vs synthetic. Firstly, 
treatment with the synthetic GC dex had no effect on AKT protein levels in the murine cell line 
(Figs 3.1 C&D), however, resulted in increased AKT expression in the human hepatoma cell 
line (Figs 3.3 C&D). Conversely, the treatment with the respective natural GCs (corticosterone 
for the murine cell line and cortisol for the human cell line) resulted in decreased AKT protein 
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levels in the BWTG3 cell line (Figs 3.2 C&D) but had no effect in the HepG2 cell line (Figs 
3.4 C&D). The results suggest that the BWTG3 cell line is likely more sensitive to its 
endogenous GC, corticosterone whereas the HepG2 cell line is likely more sensitive to 
treatment with the exogenous GC, dex. This cell line specific effects could be attributed to 
differential steroid receptor expression levels as the endogenous GCs are known to also signal 
via steroid receptors other than the GR (293).  
The literature on the effects of GCs on the protein expression of AKT is conflicting with no 
literature available, to the best of our knowledge, on the effects of GCs on AKT protein levels 
in the liver. However, AKT protein expression in muscle cells have been investigated, with 
two such in vivo studies observing either no change in muscle tissue after rats were treated with 
1 mg/kg dex for 12 days (294) or decreased AKT protein expression following treatment with 
1 mg/kg dex for 11 days (17). In contrast, a study performed by Kim & Park, et al., reported 
an increase in AKT expression after treatment with dex at the same GC concentrations used in 
the current study (219). Their study was, however, performed in C2C12 mouse muscle cells, 
treated with dex for a period of 48 hours. The study also lacks insulin-stimulation of the insulin 
signalling pathway, which could possibly have influenced the outcome in addition to length of 
treatment (219). Corticosterone treated of rats in contrast, have been demonstrated to decrease 
AKT protein levels in the hippocampus (135), which aligns with the general trend observed in 
the BWTG3 cells exposed to corticosterone in the current study.  
Co-treatment with the GCs and pro-inflammatory cytokines suggested that co-regulation does 
occur at this node, albeit pro-inflammatory cytokine specific, GC specific as well as cell line 
specific. There appears to be a tendency whereby co-treatment increases AKT protein 
expression in the BWTG3 cells (Figs 3.1 D and 3.2 C), whilst decreasing AKT protein levels 
in HepG2 cells (Fig 3.3 D).  
In the BWTG3 cells, the pro-inflammatory cytokines could co-regulate AKT expression in the 
presence of both the endogenous and exogenous GCs (Figs 3.1 D and 3.2 C), however, only 
TNF- had the ability to do so in the presence of corticosterone (100 nM and 1 M) and IL-6 
only in the presence of the highest concentration of dex (1 M). Whilst neither 1 μM dex nor 
IL-6 alone had any significant (p>0.05) effect on AKT protein expression (Figs 3.1 B, C & D), 
co-treatment with these two signalling molecules significantly (p<0.05) increased total AKT 
protein expression, suggestive of cooperativity (Fig 3.1 D). TNF-, on the other hand was able 
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to antagonise the effects of corticosterone in the BWTG3 cell line (Fig 3.2 C) displaying its 
typical opposing character towards GCs.  
In the HepG2 cells, IL-6 is the only cytokine that could co-regulate AKT protein levels and 
only in the presence of the exogenous GC, dex (Fig 3.3 D). No co-regulation occurred in 
response to treatment with the endogenous GC, cortisol in the presence of either of the 
cytokines in the human liver cell line (Fig 3.4 C&D). IL-6 is therefore able to oppose the dex-
induced increase in AKT expression, allowing for AKT protein levels to return to basal, once 
again displaying restorative action similar to that described above in the study performed by 
Kim JH, et al (292).  
Thus, the current study has shown that AKT is a node of the insulin signalling pathway, which 
is susceptible to co-regulation albeit GC specific, cytokine specific and cell-line specific. This 
is important to consider as changes in AKT protein levels will influence further downstream 
signalling which will be considered in the next sections. 
4.2.2 Phosphorylation of AKT at threonine 308 
AKT is phosphorylated at its threonine 308 residue by PDK-1 after activation of the insulin 
signalling pathway. This residue is also vulnerable to dephosphorylation by protein 
phosphatase 2A (Fig 1.1) (295). Phosphorylation at this site is essential for the activation of 
AKT and subsequent actions of the insulin (90, 95, 279). A study by Wei, et al., concluded that 
a mutation of AKT at this site to alanine could lead to decreased AKT protein levels, increase 
degradation of the protein as well as prevent the release of the enzyme from the plasma 
membrane following exposure to insulin (296) the consequences being dysregulation of the 
PI3K/AKT pathway of insulin signalling (44, 296).  
An increase in phosphorylation of AKT at threonine 308 is expected after treatment with 
insulin (297, 298) and was indeed observed in both cell lines, with similar fold induction at this 
phosphorylation site observed (Figs 3.5 – 3.8 A&B). Neither of the cytokines had the ability to 
affect the insulin-induced phosphorylation in either of the cell lines (Figs 3.5 – 3.8 A&B). To 
the best of our knowledge, phosphorylation of AKT at threonine 308 after treatment with IL-6 
has not been investigated and therefore the results of this study cannot be compared to 
literature. With regards to TNF-, Sandra, et al., found that treatment of a human squamous 
cell carcinoma cell line (SAS cells) with 10 ng/ml of the cytokine increased insulin-induced 
(100 ng/ml insulin for 5 min) phosphorylation of AKT at threonine 308 (298). This effect was, 
however, seen at shorter treatment times compared to the current study (1 hour or less versus 
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24 hours) and a restoration toward basal phosphorylation was observed after longer treatment 
durations (between 10 and 30 hours). This data suggests TNF-α is perhaps more effective to 
increase AKT phosphorylation at threonine 308 at shorter treatment times and these should be 
investigated in the hepatocyte cell models. However, the decrease to basal levels with longer 
exposure times to the pro-inflammatory cytokines observed by Sandra, et al., could possibly 
suggest that even longer exposure time might negatively affect insulin-induced threonine 308 
phosphorylation (298). 
Following treatment with dex, no effect was observed in the BWTG3 cell line (Figs 3.5 C&D). 
In contrast, treatment with dex increased the insulin-induced phosphorylation of threonine 308 
in the HepG2 cell line (Fig 3.7 C&D). Again, highlighting cell line specific effects and that the 
HepG2 cell line is more sensitive to dex than the BWTG3 cell line. The increase in AKT 
threonine 308 phosphorylation in the human hepatoma cell line is in contrast to a study 
performed by Andrade, et al., where a decrease in threonine 308 phosphorylation was observed 
after treatment with dex (218). However, this study was performed in rat mast cells, treated 
with dex for 18 hours, in the absence of insulin stimulation and in the presence of IgE directed 
antigen (218). However, the increase in insulin-induced threonine 308 phosphorylation seen in 
dex-treated HepG2 cells correlates to the increase in total AKT expression and it is therefore 
likely that the increased phosphorylation is due to the increased AKT protein expression (Figs 
3.3 C&D). The murine endogenous GC, corticosterone, like dex, had no effect on AKT 
phosphorylation at threonine 308 in the BWTG3 cell line, except at 1 M where it significantly 
(p<0.05) decreased insulin-induced phosphorylation. This decrease could be attributed to the 
decrease in total AKT expression (Fig 3.2 B&C). The human endogenous GC, cortisol 
displayed no ability to significantly (p>0.05) affect insulin-induced phosphorylation of AKT 
at threonine 308 in HepG2 cells (Figs 3.8 C&D). Literature pertaining to the effect of these 
natural GCs on AKT threonine 308 phosphorylation was, however, not found and a comparison 
cannot be made. 
In regard to possible co-regulation, co-treatment with dex in the presence of either TNF- or 
IL-6, no significant (p>0.05) co-regulation of AKT phosphorylation at threonine 308 was 
observed in either of the two cell lines (Figs 3.5 and 3.7 C&D). Co-treatment with the 
endogenous GC, corticosterone and the pro-inflammatory cytokines exhibits no significant 
(p>0.05) co-regulation in the BWTG3 cells except at the highest concentration of 
corticosterone used (Figs 3.6 C&D), where both pro-inflammatory cytokines antagonised 
corticosterone’s ability to decrease insulin-induced threonine 308 AKT phosphorylation. IL-6 
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was further able to augment insulin-stimulated AKT phosphorylation at this residue (Fig. 3.6 
D). In the HepG2 cells, only co-treatment with 100 nM cortisol and of IL-6 resulted in a 
significant (p<0.05) decrease in the insulin-induced phosphorylation of threonine 308 (Fig 3.8 
D). Like with total AKT levels no literature is available (to the best of our knowledge) 
describing AKT phosphorylation at threonine 308 in response to co-treatment with GCs and 
pro-inflammatory cytokines. The results again indicate GC-, cell line, and pro-inflammatory 
cytokine specific effects.  
4.2.3 Phosphorylation of AKT at serine 473 
Following AKT phosphorylation at threonine 308, phosphorylation at serine 473 is also 
observed. This residue is phosphorylated by mTORC2 and phosphorylation at this site in 
required for full activation of the kinase activity of AKT (44, 46, 47). Lack of serine 473 
phosphorylation still renders AKT active, however, it displays reduced kinase activity. This is 
due to the fact that serine 473 phosphorylation is required for the stabilization of threonine 308 
phosphorylation and subsequently the activation state of AKT (299, 300). Dephosphorylation 
of the serine 473 residue of AKT occurs via PP2A as well as PHLPP (Fig 1.2) (84, 85). 
Mutation of this amino acid to alanine lead to dysregulation of the AKT pathway similar to 
what was found for the threonine 308 residue (44, 296).   
Like with the threonine 308 site, an increase in phosphorylation of AKT at the serine 473 site 
is expected after treatment with insulin due to activation of the pathway (294, 297, 298). In the 
current study, the increase observed in the BWTG3 cell line (Figs 3.9 and 3.10 A&B) was more 
pronounced than in the HepG2 cell line (Figs 3.11 and 3.12 A&B), with the BWTG3 cell line 
reaching a maximal induction of 31-fold (Fig 3.10 A&B) compared to the 17-fold maximal 
induction observed in the HepG2 cells (Fig 3.12 A&B). This difference in insulin-induced 
phosphorylation of AKT at serine 473 in the two cell lines could possibly be explained by 
disparate PP2A or PHLPP levels or activity. Neither of the pro-inflammatory cytokines had 
the ability to affect the insulin-induced phosphorylation at serine 473 in either of the cell lines 
(Figs 3.9 – 3.12 A&B). Contrary to the results seen in the current study, the study by Sandra, 
et al., showed that treatment with 10 ng/ml TNF- could increase insulin-induced 
phosphorylation of AKT at the serine 473 site in SAS cells with treatment times ranging from 
1 minute up to 30 hours (298). However, similar to the current study, no change in AKT 
phosphorylation at serine 473 in human vascular endothelial cells treated with IL-6 was 
observed in a study done by Zegeye, et al (301). 
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Treatment with all concentrations of the exogenous GC (dex) did not influence the ability of 
insulin to induce phosphorylation of ATK at serine 473 in the BWTG3 cell line (Figs 3.9 C&D) 
whereas augmentation of insulin-stimulated phosphorylation of serine 473 in the HepG2 cells 
was demonstrated (Figs 3.11 C&D). Previous reports have shown that dex increases 
phosphorylation of AKT at serine 473 in either mast cells (218) or the C2C12 mouse myoblasts 
cell line (219). The difference in cell type, treatment time as well as the lack of insulin 
stimulation may account for the differences seen between the current study and the above-
mentioned studies. In contrast to dex, a general increase in insulin-induced phosphorylation of 
AKT at the serine 473 was observed after treatment with the endogenous GCs in both cell lines, 
however, this increase was only significant (p<0.05) at 1 M (Fig 3.10 and 3.12 C&D). A 
similar result was observed after treatment of C2C12 muscle cells with cortisone, the inactive 
form of the endogenous human GC (219). 
Concerning AKT phosphorylation at serine 473 in response to co-treatment with the GCs and 
pro-inflammatory cytokines some co-operative effects were observed. In the BWTG3 cell line, 
generally both the synthetic and endogenous GC co-treated with the pro-inflammatory 
cytokines portrayed co-operative activity by potentiating the insulin-induced AKT 
phosphorylation at serine 473, except for 1 M corticosterone in the presence of IL-6 and 1 M 
dex in the presence of TNF-, where antagonism of the GC response was observed in response 
to the pro-inflammatory cytokine (Fig. 3.9 C&D and Fig.3.10 C&D). This increase suggests a 
co-operative effect between the GC and the pro-inflammatory cytokine as on their own, neither 
generally induced a response (Fig 3.9 A–D). The endogenous hormone corticosterone 
exhibited cooperativity with TNF-α, however, only at the two highest concentrations tested 
probably due to its lower potency via the GR (Fig.3.10 C). Taken together this would suggest 
that cooperativity between the GCs and pro-inflammatory cytokines is concentration 
dependent and in terms of corticosterone also cytokine specific. 
Curiously co-treatment with dex and both pro-inflammatory cytokines in the HepG2 cells only 
portrayed cooperativity at the highest (1 M) dex concentration used, whereas antagonism by 
the cytokines were observed at the lower concentrations dex (Fig. 3.11 C&D), again, 
highlighting the dependence of cooperativity on the concentration of GC present in addition to 
the cell line used when considering insulin stimulated AKT phosphorylation of serine 473 by 
GCs and cytokines. 
Stellenbosch University  https://scholar.sun.ac.za
 
77 
To summarise, a general increase in insulin-induced phosphorylation of AKT at either site 
following co-treatment with TNF- was observed in the BWTG3 cells, regardless of the GC 
involved. In the HepG2 cells, TNF-  has the ability to increase or decrease insulin-induced 
phosphorylation of AKT at serine 473, regardless of the GC present. Furthermore, at serine 473 
in the HepG2 cells, the cytokines act in a similar manner to one another when co-treated with 
dex. Co-treatment with IL-6 generally leads to a decrease in the insulin-induced 
phosphorylation of AKT at both the threonine 308 and serine 473 site. However, IL-6 displays 
the ability to increase phosphorylation in both cell lines and in the presence of either of the 
GCs and dependent on the concentration GC used. Together the results suggest that AKT may 
be considered a node within the insulin signalling pathway that is co-regulated by stress and 
inflammatory mediators. The test compounds appear to have the greatest potential of co-
regulating the phosphorylation at serine 473 rather than threonine 308. This difference suggests 
that they perhaps have the ability to affect mTORC2 responsible for the phosphorylation of 
AKT at serine 473. Downstream of AKT is GSK-3, which is inhibited via phosphorylation by 
activated AKT and might be affected by the co-regulation observed for AKT by the GCs and 
pro-inflammatory cytokines.  
4.3 Effects of the test compounds on the protein expression and tyrosine 
phosphorylation of GSK-3 
The serine/threonine kinase GSK-3 has multiple substrates including GS, the enzyme 
responsible for the synthesis of glycogen, which it phosphorylates and subsequently inactivates 
(50, 51). Active GSK-3 is therefore important for the inhibition of the enzyme, leading to 
decreased glycogen synthesis. Additionally, GSK-3 is also responsible for the inactivation of 
IRS-1 thereby leading to disruption in insulin signal transduction (302) GSK-3 is considered 
to be auto-phosphorylated at specific tyrosine residues, which is responsible for its kinase 
activity (49). 
4.3.1 Protein expression of GSK-3 
Dysregulation of GSK-3 has been implicated in the disease progression of T2DM (50, 122–
125). A lack of GSK-3, in the presence of GSK-3 in mouse models results in the death of 
these mice in the early stages of embryo development, whereas the opposite (GSK-3 present 
with a lack of GSK-3) improved insulin sensitivity and glucose tolerance (303, 304). For this 
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reason, it is safe to assume that GSK-3 is the subtype of the enzyme most important with 
regards to insulin signalling.  
In the current study, stimulation with insulin had no effect on the GSK-3 or GSK-3 protein 
levels in both the murine and human hepatoma cell line (Figs 3.13 A-D and 3.15 A-D). 
Similarly, the presence of either of the pro-inflammatory cytokines did not influence GSK-3 
protein expression for either of the subtypes (Figs 3.13 A-D and 3.15 A-D). Wang and 
colleagues demonstrated (albeit only with one unquantified blot) that treatment with 20 ng/ml 
TNF- did not affect the GSK-3 protein expression (305). However, this was in the PC3 
prostate cancer cell line as the effects of TNF- and IL-6 on the protein expression of GSK-3 
has not been investigated in hepatocytes, to the best of our knowledge. 
Neither of the GCs affected the protein expression of GSK- in the murine and human 
hepatoma cell lines (Figs 3.14 A&B and Figs 3.16 A&B). In contrast, treatment with both the 
endogenous and exogenous GCs increased protein expression of the GSK-3 subtype in the 
BWTG3 cell line (Figs 3.14 C&D), whilst only the natural ligand, cortisol, increased the 
protein expression of the beta subtype of the enzyme in the HepG2 cells (Figs 3.16 C&D). 
Similar to our results, GSK-3α protein levels were unaffected in muscles of dex-treated rats, 
although the authors of this study also observed no effect on GSK-3 protein expression, which 
was not demonstrated in the current study (294). These results suggest that the GCs might 
influence insulin signalling by increasing GSK-3 protein levels.  
Similar to the individual treatments, co-treatment with the GCs and pro-inflammatory 
cytokines had no effect on the protein levels of GSK-3 in both the murine and human 
hepatoma cell lines, although a slight decrease in GSK-3 levels were observed when dex was 
co-treated with IL-6 (Figs 3.14 A&B and Figs 3.16 A&B). Thus, only co-treatment with dex 
and IL-6 can be considered to exhibit co-regulation of GSK-3 protein levels, even though 
only a small but significant (p<0.05) decrease was shown (Fig.3.14 B) In contrast, increased 
GSK-3 protein levels in response to the endogenous GCs in both murine and human hepatoma 
cell lines were generally antagonised by IL-6 (Fig. 3.14 D and Fig. 3.16 D), whilst co-treatment 
with TNF- had no effect (Fig.3.14 C and Fig. 3.16 D). Antagonism of corticosterone-induced 
GSK-3 protein expression by IL-6 in the murine hepatoma cell line especially was quite 
pronounced as GSK-3 protein levels were decreased by approximately 40% below basal 
levels (Fig. 3.14 D). Although no significance could be established, dex-mediated increase of 
GSK-3 protein levels was decreased to basal levels in BWTG3 cells (Fig. 3.14). Taken 
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together TNF-α, which exhibited no co-regulation, will have no influence on the GCs to 
influence insulin signalling via GSK-3β, whereas IL-6 could potentially obstruct this, although 
in a cell line specific manner.  
4.3.2 Tyrosine phosphorylation of GSK-3 
GSK-3 is highly phosphorylated at key tyrosine residues in its active state, however, the 
mechanism of regulation of this phosphorylation event is not yet well understood (306). 
Autophosphorylation is one proposed mechanism (307). Phosphorylation at these sites is 
crucial for its kinase activity as mutations at these residues to alanine impairs the function of 
the protein (48, 121). Active GSK-3 causes the phosphorylation of GS, decreasing glycogen 
synthesis, as well as inactivating IRS-1 through serine phosphorylation (302, 308). T2DM has 
been linked to a decrease in GS activity and glycogen synthesis, as well as the inability of 
IRS-1 to take part in the insulin signalling cascade, which is attributed to dysfunctional GSK3 
signalling (50, 122–124). 
Just as with the protein expression of GSK-3, no change was observed in the tyrosine 
phosphorylation after treatment with insulin in the absence or presence of either of the pro-
inflammatory cytokines in both the murine and human hepatoma cell lines (Figs 3.17 A-D and 
3.19 A-D). Similarly, dex had no effect on the phosphorylation of GSK-3 or GSK-3 in both 
cell lines used (Figs 3.18 A-D and 3.20 A-D), whereas the endogenous GC exhibited cell line 
specific effects. In the BWTG3 cell line, the endogenous GC, corticosterone, decreased 
tyrosine phosphorylation of both GSK-3 subtypes (Figs 3.18 A-D) whilst treatment with the 
endogenous GC, cortisol, resulted in increased tyrosine phosphorylation of both GSK-3 
subtypes in the HepG2 cells (Figs 3.20 A-D). To the best of our knowledge, no studies have 
investigated the effects of GCs on the tyrosine phosphorylation of GSK-3 and therefore, we 
cannot make a comparison to the literature. Increased GSK-3 tyrosine phosphorylation of both 
subtypes is indicative of a more catalytically active enzyme and thus the endogenous GC in the 
human hepatoma cell line could potentially greatly influence GS activity and negatively 
influencing insulin signalling via IRS-1. This however would not be observed in the BWTG3 
cells due to the decrease in tyrosine phosphorylation observed, although further investigation 
is required to test this hypothesis.  
When looking at the co-treatment of the GCs with the pro-inflammatory cytokines, TNF-α in 
the presence of the GCs generally either increased tyrosine phosphorylation of both GSK-3 
subtypes or had no effect compared to GC treatment only (Fig. 3.18 A&C and Fig. 3.20 A&C). 
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In the murine hepatoma cell lines, although no significant (p>0.05) co-regulation could be 
established, GC co-treatment with TNF-α restored tyrosine phosphorylated levels of both 
GSK-3 subtypes to basal levels and in the case of GSK-3β, co-treatment with dex significantly 
(p<0.05) increased it above basal (Fig. 3.18 A&C). In contrast, in the HepG2 cells, TNF-α with 
both endogenous and synthetic GC exhibited cooperative regulation, increasing tyrosine 
phosphorylation of both GSK-3 subtypes (Fig. 3.20 A&C). Unlike TNF-α, co-treatment with 
IL-6 elicited differential effects depending on the GC as well as the cell line used (Fig. 3.18 
B&D and Fig.3.20 B&D). Corticosterone-induced inhibition of tyrosine phosphorylation of 
both GSK-3 subtypes was antagonised by IL-6 back to basal levels in BWTG3 cells (Fig. 3.18 
B&D), whilst dex co-treatment with IL-6 had no effect on basal tyrosine phosphorylation of 
GSK-3α, this co-treatment did decrease basal GSK-3β tyrosine phosphorylation, suggesting 
that exposure to dex and IL-6 could possible negatively affect GSK-3β signalling and 
subsequent GS and IRS-2 inactivation.  
In contrast to the co-treatments in the BWTG3 cells, GCs co-treated with the pro-inflammatory 
cytokines generally exhibited co-operative effects in the HepG2 cells, except for IL-6 co-
treated with cortisol where no cooperativity was observed (Fig.3.20). Nonetheless, co-
treatment conditions with either cytokine significantly (p<0.05) increased tyrosine 
phosphorylation of both GSK-3 subtypes indicative of a more catalytically active GSK-3 in the 
HepG2 cell line. Increased GSK-3β tyrosine phosphorylation also holds great importance as it 
is said to have more potential substrates than any other kinase (281, 309). The mechanism 
responsible for this increase in phosphorylation of GSK-3 subtypes at their respective tyrosine 
residues remains to be elucidated and could potentially involve increased intracellular calcium 
levels, which have been reported to induce tyrosine phosphorylation of GSK-3β (310). 
Additionally, cAMP levels could be increased by this co-treatment, which have also been 
shown to activate GSK-3 via a cAMP-activated protein tyrosine kinase (311). These could 
serve as future investigations into understanding the molecular mechanism involved in the co-
operative regulation of GSK-3 by the GCs and pro-inflammatory cytokines.  
4.4 Effects of the test compounds on the mRNA expression of G6Pase 
One of the main functions of insulin in the liver is the inhibition of glucose production either 
from gluconeogenesis or glycogenolysis. The final reaction within these two pathways is 
catalysed by G6Pase, which hydrolyses glucose-6-phosphate releasing glucose, thereby 
increasing blood glucose levels (112, 113). The protein expression of G6Pase has been reported 
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to significantly increase during starvation, as well as T2DM (312). G6Pase activity as well as 
levels are negatively affected by insulin (106, 283) and thus could be considered another node 
(or target) within the insulin signalling pathway. Uncontrolled increased expression of the gene 
encoding this protein could lead to elevated hepatic glucose production and hyperglycaemia, 
which ultimately leads to T2DM.  
Whilst insulin has been reported to decrease G6Pase levels (313), in this study this was only 
observed in the HepG2 cells as insulin stimulation for 30 minutes was unable to decrease 
G6Pase mRNA expression in the BWTG3 cells (Fig 3.21 A and Fig. 3.22). This would suggest 
that downstream signalling of insulin is much less responsive in the murine hepatoma cell line 
than in the HepG2 cells, at least when considering the pathway involved in G6Pase regulation 
i.e., FOXO1 regulation. Future studies could potentially consider exposing the BWTG3 cells 
to insulin for longer, which might be required to successfully decrease G6Pase mRNA.  
Regarding the effect of the pro-inflammatory cytokines on G6Pase mRNA expression, TNF- 
had no effect on G6Pase mRNA levels in either of the cell lines, although it did restore the 
insulin-induced decrease of G6Pase mRNA levels to basal expression in the HepG2 cells, 
although significance could not be established when compared to insulin-only treatment (Figs 
3.21 and 3.22 A). Similar to the current study, work done by Grempler, et al., showed that 
treatment with 10 ng/ml TNF- for 3 hours was able to decrease dex-induced G6Pase mRNA 
expression in H4IIE rat hepatoma cells, in the absence and presence of insulin (112). 
Furthermore, treatment of mice with 5 or 10 g TNF- for 12 hours resulted in decreased 
G6Pase mRNA levels in the liver (314). Unlike TNF-α, IL-6 in the presence of insulin 
decreased G6Pase mRNA expression in the BWTG3 cell line (Fig 3.21 A). Decreased mRNA 
expression observed in response to IL-6 is in agreement with a study performed in mice bearing 
IL-6-secreting tumours (315). In contrast and similar to TNF-α, IL-6 attenuated the insulin-
induced decrease in G6Pase mRNA levels to that of basal expression in the human hepatoma 
cell line, although not significantly (p>0.05) different to insulin-only treatment (Fig.3. 22 A). 
These results might be related to the lack of insulin-induced inhibition of G6Pase mRNA in 
the BWTG3 cells in comparison to the human hepatoma cell line. IL-6 might only be able to 
inhibit G6Pase mRNA expression when insulin is unable to affect the mRNA levels of the 
gluconeogenic enzyme. This could possibly be due to a different milieu of transcription factors 
occupying the G6PC promoter in the event of insulin-induced repression of the promoter 
compared to the lack thereof. Future studies could investigate this hypothesis by looking at the 
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recruitment of transcription factors associated with G6Pase regulation such as FOXO1 (97) or 
hepatic nuclear factor 1 (212) using chromatin immunoprecipitation assays. 
GCs are known to increase G6Pase mRNA expression due to the GREs present in the G6PC 
promoter (52, 98, 109, 209, 213–215, 316). As expected, dex significantly (p<0.05) increased 
G6Pase mRNA expression at all the concentrations tested in the HepG2 cells (Fig. 3.22 B&C), 
whereas only at the lowest concentration used i.e., 10 nM, was able to significantly (p<0.05) 
induce G6Pase mRNA levels above basal in the murine hepatoma cell line (Fig. 3. 21 B&C). 
This coincides with the previously mentioned view (section 4.2.1) that the HepG2 cell line 
appears to be more sensitive to dex. Although it should be mentioned that in the HepG2 cells, 
insulin treatment resulted in a decrease in G6Pase mRNA expression, which was attenuated by 
dex and thus the effect of insulin or lack thereof, as is in the case of the BWTG3 cells, could 
possibly influence the dex-mediated effect on G6Pase mRNA expression. In addition, insulin 
has been reported to attenuate dex-mediated increase in G6Pase mRNA expression in Fao and 
H4IIE rat hepatoma cells (112), which was not observed in the current study. This, however, 
could be due to the concentration of insulin used as the above-mentioned studies used much 
higher insulin concentrations, in addition to exposing the cells to insulin for a much longer 
period. 
In regard to the effect of co-treatment of dex with a pro-inflammatory cytokine, significant 
(p<0.05) co-regulation was only observed with TNF-α and only at the lowest concentration of 
dex used (10 nM) in both cell lines (Fig.3.21 B&C and Fig.3.22 B&C). TNF-α was able to 
antagonise the dex-mediated increase in G6Pase mRNA expression as previously reported 
(112) and thus would prevent hepatic glucose production. In contrast, IL-6 had no significant 
(p>0.05) effect on the dex-mediated increase in G6Pase mRNA, although generally levels 
returned to that of insulin-only treated levels.  
To summarise, co-regulation was observed at this node of the insulin signalling pathway, albeit 
cytokine specific. This cytokine specific effect can be attributed to the different signalling 
mechanisms of these two cytokines that essentially will activate different transcription factors 
responsible for gene regulation (reviewed in Chapter 1, sections 1.6.1 and 1.6.2).  
4.5 Conclusions and implications for future work 
To conclude, the GCs and cytokines pertaining to this study were capable of co-regulating each 
of the different nodes of the insulin signalling investigated in this study, except GSK-3 protein 
expression. However, the results are GC specific, cytokine specific as well as cell line (species) 
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specific. Antagonistic effects were observed, as expected, since these biological mediators 
primarily act in an antagonistic manner towards each other (195, 202). However, co-operative 
effects were also observed between the cytokines and GCs. This is not completely unexpected, 
as it has been shown that certain GCs and cytokines have the ability to co-regulate certain acute 
phase proteins (244, 259–262) although the molecular mechanism remains to be elucidated. In 
addition, co-regulation of the acute phase proteins is generally believed to be at the 
transcriptional level whereas in the current study we show that co-regulation also occurs at 
non-genomic events. For example, co-regulation was able to increase the insulin-induced 
phosphorylation effects seen at the threonine 308 and serine 473 sites of AKT, suggesting that 
it could potentially lead to increased insulin sensitivity as opposed to insulin resistance as 
expected. However, it should be noted that increased basal AKT signalling has also been 
implicated in insulin resistance due to an increase in lipid synthesis and oxidative stress (317). 
Furthermore, with increased AKT signalling, pro-longed ribosomal protein S6 kinase beta-1 
(S6K) activation might occur, which is responsible for the deactivation of IRS1. This negative 
feedback loop is responsible for signal termination and dysregulation through increased basal 
AKT signalling could lead to subsequent insulin resistance.  
Whether the co-regulation of these non-genomic effects are due to the transcriptional activity 
of the ligand-activated GR remains to be explored. Additionally, it still remains unclear 
whether simultaneous, rather than sequential exposure to both GCs and pro-inflammatory 
cytokines, which occurs in vivo, would result in an insulin resistant state. The current study 
only looked at one time point (24 hours) for all treatment condition, and longer or shorter 
exposure times to the test compounds might have a different effect on any insulin-mediated 
responses. It cannot be expected that all insulin regulated effects will become unresponsive to 
insulin i.e., insulin resistant, at similar exposure times. Future studies should thus also consider 
different treatment times. Additionally, whether co-treatment with GCs and pro-inflammatory 
cytokines take part in the negative feedback loop, which involves inhibitory serine residues of 
IR and IRS, which become phosphorylated by AKT after insulin stimulation should be 
investigated as excessive serine phosphorylation of these proteins would lead to disrupted 
insulin signalling. The effect of co-treatment with GCs and pro-inflammatory cytokines on 
PEPCK mRNA expression, another key gluconeogenic enzyme, as well as the protein 
expression and enzymatic activity, of both G6Pase and PEPCK could be explored, as mRNA 
expression does not necessarily equate to similar protein levels. And finally, the insulin-
mediated inhibition of hepatic glucose production in response to GCs and pro-inflammatory 
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cytokine co-treatment should also be investigated as this is a hallmark of a hepatic insulin 
resistant state.  
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A1. BWTG3 and HepG2 cells used in this study were tested for mycoplasma every quarter and 
were mycoplasma negative.  
Routine testing for mycoplasma was done as this infection is difficult to detect as these microorganisms 
do not adhere to cell surfaces, do not contain a cell wall and cannot be seen with the naked eye as they 
do not cause visible turbidity. These micro-organisms are also able to avert the antibiotics commonly 
used for tissue culture in this study. Therefore, this kind of infection can go undetected for months 
without notice. Contamination of this nature affects cell growth as well as experimental results, thereby 
skewing the data, resulting in inaccurate reporting. For this reason, the cells in this study were tested 
once every 3 months. The Hoechst-dye stains only DNA containing nuclei. Therefore, any fluorescence 
found around the cells (would be visible as little spots between cells) would indicate contamination 
with mycoplasma.  
 
 
Figure A1. Mycoplasma negative BWTG3 (A) and HepG2 (B) cells. Cells were fixed with methanol and glacial 
acetic acid in a 3:1 ratio before staining with the DNA Hoechst 33258 dye (Sigma-Aldrich, SA). The Hoechst-
dye only stains DNA-containing nuclei. Fluorescent images were obtained using the Olympus XI81 inverted 
fluorescent microscope.  
  




A2. RNA isolated from BWTG3 and HepG2 cells were intact.  
RNA concentration and purity were determined using the Nanodrop ND-1000. Further validation of the 
integrity of the RNA was done by separating RNA samples on a 1% (w/v) agarose gel stained with 
Nancy-520 (Sigma-Aldrich). The presence of undamaged 28S and 18S ribosomal bands indicates that 
the RNA can be used to continue with synthesis of cDNA.  
 
 
Figure A2. Representative 1% denaturing agarose gel indicating intact RNA isolated from BWTG3 and 
HepG2 cells. Total RNA was isolated from BWTG3 (A) and HepG2 (B) cells. RNA was isolated using Tri-
reagent as described in Chapter 2, section 2.3. A total of 1 μg RNA was loaded onto the agarose gel and visualized 
with Nancy-520 nucleic acid stain. Lanes: 1) TNF-; 2) IL-6; 3) 10 nM dex; 4) 100 nM dex; 5) 1M dex; 6) 10 
nM dex + TNF-; 7) 100 nM dex + TNF-; 8) 1 M dex + TNF-; 9) 10 nM dex + IL-6; 10) 100 nM dex + IL-
6; 11) 1 M dex + IL-6 
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A3. The correct human G6Pase qPCR product was confirmed with agarose gel 
electrophoresis. 
In order to determine that the correct product was amplified during qPCR, the product was separated 
using 3% (w/v) agarose gel electrophoresis and visualised with Nancy-520 nucleic acid stain. The size 
of the product was compared to a 100 bp DNA ladder as the amplicon was expected to be 141 bp in 
size. The melting curve for the qPCR product is also included below (Fig A3.2). Peaks found at 82 
degrees represent the template containing samples and peaks seen between 72.00 and 74.00 degrees 
represent non-template controls. A possible reason for seeing the peaks at the lower temperature is 
primer dimer formation. The fact that these peaks are not present in the samples containing template 
suggests the primer is specific enough to use for amplification. Primer efficiency was also determined 
using a dilution series containing cDNA from untreated HepG2 cells and the standard curve can be seen 
in figure A3.3. 
 
Figure A3.1. Representative agarose gel indicating qPCR product of human G6Pase gene used in this study. 
PCR products were subjected to agarose (3% w/v) gel electrophoresis and visualised with Nancy-520 nucleic acid 
stain. O’GeneRuler 100bp DNA ladder was used (ThermoFisher Scientific, USA); NTC: non-template control; 
Veh: sample treated with vehicle (DMEM-full). 
141 bp 




Figure A3.2. Melting curve for the above product gel. Peaks seen around 82.00 degrees indicate the samples 




Figure A3.3. Standard curve used to determine primer efficiency of human G6Pase primers. 
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